<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">marinedrugs</journal-id>
      <journal-title>Marine Drugs</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Mar. Drugs</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Marine Drugs</abbrev-journal-title>
      <issn pub-type="epub">1660-3397</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/md10102181</article-id>
      <article-id pub-id-type="publisher-id">marinedrugs-10-02181</article-id>
      <article-categories>
        <subj-group>
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Marine Cyanobacteria Compounds with Anticancer Properties: A Review on the Implication of Apoptosis</article-title>
      </title-group>
      
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Margarida</given-names>
          </name>
          <xref rid="af1-marinedrugs-10-02181" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa-Rodrigues</surname>
            <given-names>João</given-names>
          </name>
          <xref rid="af2-marinedrugs-10-02181" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Maria Helena</given-names>
          </name>
          <xref rid="af2-marinedrugs-10-02181" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barros</surname>
            <given-names>Piedade</given-names>
          </name>
          <xref rid="af3-marinedrugs-10-02181" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vasconcelos</surname>
            <given-names>Vitor</given-names>
          </name>
          <xref rid="af1-marinedrugs-10-02181" ref-type="aff">1</xref>
          <xref rid="af4-marinedrugs-10-02181" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Rosário</given-names>
          </name>
          <xref rid="af1-marinedrugs-10-02181" ref-type="aff">1</xref>
          <xref rid="af3-marinedrugs-10-02181" ref-type="aff">3</xref>
          <xref rid="af5-marinedrugs-10-02181" ref-type="aff">5</xref>
          <xref rid="c1-marinedrugs-10-02181" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-marinedrugs-10-02181"><label>1 </label>Marine and Environmental Research Center—CIIMAR/CIMAR, Porto University, Rua dos Bragas, 289, 4050-123 Porto, Portugal; Email: <email>costa.anamarg@gmail.com</email> (M.C.); <email>vmvascon@fc.up.pt</email> (V.V.)</aff>
      <aff id="af2-marinedrugs-10-02181"><label>2 </label>Laboratory of Pharmacology and Cellular Biocompatibility, Faculty of Dental Medicine, Porto University, Rua Dr. Manuel Pereira da Silva, 4200-393 Porto, Portugal; Email: <email>jrodrigues@fmd.up.pt</email> (J.C.-R.); <email>mhfernandes@fmd.up.pt</email> (M.H.F.)</aff>
      <aff id="af3-marinedrugs-10-02181"><label>3 </label>Centre of Health and Environmental Research—CISA, Superior School of Health Technology of Porto, Polytechnic Institute of Porto, Rua Valente Perfeito, 322, 4400-330 Vila Nova de Gaia, Portugal; Email: <email>pgb@estsp.ipp.pt</email></aff>
      <aff id="af4-marinedrugs-10-02181"><label>4 </label>Faculty of Sciences, Porto University, Rua do Campo Alegre, 4169-007 Porto, Portugal</aff>
      <aff id="af5-marinedrugs-10-02181"><label>5 </label>Institute for Molecular and Cell Biology—IBMC, Porto University, Rua do Campo Alegre 823, 4150-180 Porto, Portugal</aff>
      <author-notes>
        <corresp id="c1-marinedrugs-10-02181"><label>*</label> Author  to whom correspondence should be addressed; Email: <email>mrm@estsp.ipp.pt</email>; Tel.: +351-22-340-18-00; Fax: +351-22-339-06-08.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>09</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="collection"><month>10</month>
        <year>2012</year>
      </pub-date>
      <volume>10</volume>
      <issue>10</issue>
      <fpage>2181</fpage>
      <lpage>2207</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>08</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>11</day>
          <month>09</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>09</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>©  2012 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>Marine cyanobacteria have been considered a rich source of secondary metabolites with potential biotechnological applications, namely in the pharmacological field. Chemically diverse compounds were found to induce cytoxicity, anti-inflammatory and antibacterial activities. The potential of marine cyanobacteria as anticancer agents has however been the most explored and, besides cytotoxicity in tumor cell lines, several compounds have emerged as templates for the development of new anticancer drugs. The mechanisms implicated in the cytotoxicity of marine cyanobacteria compounds in tumor cell lines are still largely overlooked but several studies point to an implication in apoptosis. This association has been related to several apoptotic indicators such as cell cycle arrest, mitochondrial dysfunctions and oxidative damage, alterations in caspase cascade, alterations in specific proteins levels and alterations in the membrane sodium dynamics. In the present paper a compilation of the described marine cyanobacterial compounds with potential anticancer properties is presented and a review on the implication of apoptosis as the mechanism of cell death is discussed. </p>
      </abstract>
      <kwd-group>
        <kwd>cancer</kwd>
        <kwd>apoptosis</kwd>
        <kwd>marine cyanobacteria</kwd>
        <kwd>natural compounds</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>1. Introduction</title>
      <p>Cyanobacteria are a diverse group of prokaryotic organisms that can exist in a wide range of ecosystems. Capable to develop photosynthesis, cyanobacteria constitute one of the components of the primary first level organisms in water food chains. These organisms have also important roles in nutrient cycles such as nitrogen cycle, by converting atmospheric nitrogen into an organic form, in a process that releases some residual hydrogen [<xref ref-type="bibr" rid="B1-marinedrugs-10-02181">1</xref>].</p>
      <p>The first studies concerning cyanobacteria were focused on their ecological and public heath impact, due to their capacity to produce toxins with deleterious effects on plants, invertebrates and vertebrates, including humans [<xref ref-type="bibr" rid="B2-marinedrugs-10-02181">2</xref>,<xref ref-type="bibr" rid="B3-marinedrugs-10-02181">3</xref>]. In humans, toxins such as microcystins, nodularins and cylindrospermopsin were found to induce liver and kidney damage, cytotoxicity, neurotoxicity, dermal toxicity, gastrointestinal disturbances among others [<xref ref-type="bibr" rid="B4-marinedrugs-10-02181">4</xref>]. More recently, several studies have demonstrated that cyanobacteria also produce compounds with biotechnological and pharmaceutical interest. Important biological properties such as anticancer, anti-inflammatory and antibiotic activities have been described [<xref ref-type="bibr" rid="B5-marinedrugs-10-02181">5</xref>].</p>
      <p>Marine cyanobacteria in particular have been considered a prominent source of structurally diverse and biologically active natural products [<xref ref-type="bibr" rid="B6-marinedrugs-10-02181">6</xref>]. The diversity in secondary metabolites is a result of the cyanobacterial capacity to integrate both Non-Ribosomal Peptide Synthethases with Polyketide Synthases. Cyanobacteria have a wide range of enzymes responsible for methylations, oxidations, tailoring and other alterations [<xref ref-type="bibr" rid="B7-marinedrugs-10-02181">7</xref>], resulting in chemically diverse natural products such as linear peptides [<xref ref-type="bibr" rid="B8-marinedrugs-10-02181">8</xref>], cyclic peptides [<xref ref-type="bibr" rid="B9-marinedrugs-10-02181">9</xref>], linear lipopeptides [<xref ref-type="bibr" rid="B10-marinedrugs-10-02181">10</xref>], depsipeptides [<xref ref-type="bibr" rid="B11-marinedrugs-10-02181">11</xref>], cyclic depsipeptides [<xref ref-type="bibr" rid="B12-marinedrugs-10-02181">12</xref>], fatty acid amides [<xref ref-type="bibr" rid="B13-marinedrugs-10-02181">13</xref>], swinholides [<xref ref-type="bibr" rid="B14-marinedrugs-10-02181">14</xref>], glicomacrolides [<xref ref-type="bibr" rid="B15-marinedrugs-10-02181">15</xref>] or macrolactones [<xref ref-type="bibr" rid="B16-marinedrugs-10-02181">16</xref>].</p>
      <p>A large diversity of biological interactions is described between marine cyanobacteria compounds and several groups of organisms, such as bacteria [<xref ref-type="bibr" rid="B17-marinedrugs-10-02181">17</xref>], fungi [<xref ref-type="bibr" rid="B18-marinedrugs-10-02181">18</xref>,<xref ref-type="bibr" rid="B19-marinedrugs-10-02181">19</xref>] parasites [<xref ref-type="bibr" rid="B20-marinedrugs-10-02181">20</xref>] and invertebrates [<xref ref-type="bibr" rid="B21-marinedrugs-10-02181">21</xref>]. The role of the compounds in marine environment has been rarely elucidated but a possible explanation is that they represent a defensive handling to the surrounding predators [<xref ref-type="bibr" rid="B22-marinedrugs-10-02181">22</xref>]. In what concerns to humans, anti-inflammatory [<xref ref-type="bibr" rid="B23-marinedrugs-10-02181">23</xref>] neurotoxic [<xref ref-type="bibr" rid="B12-marinedrugs-10-02181">12</xref>] and anticancerigenous [<xref ref-type="bibr" rid="B24-marinedrugs-10-02181">24</xref>] are common bioactive properties. The cytotoxic effects of marine cyanobacteria compounds on human tumor cell lines are the most studied, with some compounds producing effects at the nanomolar range [<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>]. As examples, apratoxin D, produced by species of <italic>Lyngbya</italic> is potently cytotoxic to human lung cancer cells [<xref ref-type="bibr" rid="B26-marinedrugs-10-02181">26</xref>] and likewise, symplocamide A, isolated from <italic>Symploca </italic>sp. showed also potent cytotoxicity to lung cancer cells and neuroblastoma cells [<xref ref-type="bibr" rid="B27-marinedrugs-10-02181">27</xref>]. </p>
      <p>Cell death is crucial in cancer therapy. Comparing cell death mechanisms in neoplastic cells, apoptosis reveals its importance when compared with necrosis since it occurs as a physiological process to any mild cell injury or simply when cell function is finished or disturbed, occurs via a predictable and coordinated pathway, and cellular deletion does not involve inflammation [<xref ref-type="bibr" rid="B28-marinedrugs-10-02181">28</xref>]. In contrast, necrosis is difficult to prevent and always develops an inflammatory response and death of the surrounding cells [<xref ref-type="bibr" rid="B29-marinedrugs-10-02181">29</xref>]. Autophagy, also described as a mechanism of cell death, is likewise indicated as a cancer therapeutic target. However, it has a dual effect since maintaining cell survival can promote the growth of established tumors [<xref ref-type="bibr" rid="B30-marinedrugs-10-02181">30</xref>]. Several anticancer drugs work as apoptotic modulators, in order to eliminate silent and cleanly the unwanted cells [<xref ref-type="bibr" rid="B31-marinedrugs-10-02181">31</xref>,<xref ref-type="bibr" rid="B32-marinedrugs-10-02181">32</xref>]. Marine cyanobacteria were found to produce a wide range of compounds that revealed apoptotic properties. Apoptosis can be induced by both intrinsic and extrinsic signals, by multiple agents, as the natural flavonoid quercetin [<xref ref-type="bibr" rid="B33-marinedrugs-10-02181">33</xref>], the representative reactive oxygen species H<sub>2</sub>O<sub>2</sub> [<xref ref-type="bibr" rid="B34-marinedrugs-10-02181">34</xref>] or even the UV radiation [<xref ref-type="bibr" rid="B35-marinedrugs-10-02181">35</xref>]. Apoptotic cells develop typical morphological alterations that allow its identification. During an early stage of apoptosis, called cell shrinkage, cells have a smaller size, showing a dense cytoplasm with thinner organelles [<xref ref-type="bibr" rid="B36-marinedrugs-10-02181">36</xref>]. Martins and co-workers demonstrated that HL-60 cells exposed to aqueous extracts of <italic>Synechocystis </italic>sp. and <italic>Synechococcus </italic>sp. strains, presented cell shrinkage showing that cells were developing apoptosis, and membrane budding, that occurs when cell is fragmented into apoptotic bodies [<xref ref-type="bibr" rid="B37-marinedrugs-10-02181">37</xref>]. Apoptotic cells also develop nuclear alterations, visible as nuclear fragmentation and chromatin condensation [<xref ref-type="bibr" rid="B36-marinedrugs-10-02181">36</xref>]. Biselyngbyaside, a macrolide glycoside produced by <italic>Lyngbya </italic>sp., was found to induce apoptosis in mature osteoclasts, revealed by nuclear condensation [<xref ref-type="bibr" rid="B38-marinedrugs-10-02181">38</xref>]. Marine benthic <italic>Anabaena</italic> sp. extracts were found to induce apoptosis in acute myeloid leukemia cell line, with cells showing several described typical morphological markers, such as chromatin condensation, nuclear fragmentation, surface budding and release of apoptotic bodies [<xref ref-type="bibr" rid="B39-marinedrugs-10-02181">39</xref>]. </p>
      <p>Besides morphological markers that allow the direct identification of an apoptotic cell, some other cellular and molecular alterations associated to apoptosis can be identified. Since several marine cyanobacteria compounds interact with important molecular targets involved in anticancer activity leading to a controlled death of tumor cells, this review aims to resume the marine cyanobacterial products that were found to inhibit the proliferation of cancer cell lines, namely by inducing apoptotic cell death. Effects of compounds on cell cycle arrest, mitochondrial dysfunctions and oxidative damage, alterations in caspase cascade, non-caspases proteases involvement, alterations in the Bcl-2 protein family and alterations in membrane sodium channel dynamics are reviewed. In order to summarize the data available in the literature, in <xref ref-type="table" rid="marinedrugs-10-02181-t001">Table 1</xref> we present the described cyanobacterial compounds that were found to induce cytotoxic effects on a wide range of cancer cell line, and in <xref ref-type="table" rid="marinedrugs-10-02181-t002">Table 2</xref> we describe the most relevant effects related to anticancer activity induced by marine cyanobacteria compounds.</p>
      <table-wrap id="marinedrugs-10-02181-t001" position="float">
        <object-id pub-id-type="pii">marinedrugs-10-02181-t001_Table 1</object-id>
        <label>Table 1</label>
        <caption>
          <p>Marine cyanobacteria compounds with potential anticancer properties.</p>
        </caption>
            <table>
          <thead>
            <tr>
              <th align="center" valign="middle">Compound</th>
              <th align="center" valign="middle">Source</th>
              <th align="center" valign="middle">Class of compound</th>
              <th align="center" valign="middle">Cytoxicity assay</th>
              <th align="center" valign="middle">Human cell line tested</th>
              <th align="center" valign="middle">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="2" align="center" valign="middle">Ankaraholide A</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Geitlerinema</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Glycosilated swinholide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">NCI-H460 lung tumor</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B14-marinedrugs-10-02181">14</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">SRB</td>
              <td align="center" valign="middle">MDA-MB-435 breast carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B14-marinedrugs-10-02181">14</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Apratoxin A</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">SRB</td>
              <td align="center" valign="middle">KB oral epidermoid cancer and LoVo colon cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B40-marinedrugs-10-02181">40</xref>,<xref ref-type="bibr" rid="B41-marinedrugs-10-02181">41</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">U2OS osteosarcoma, HT29 colon adenocarcinoma and HeLa cervical carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B42-marinedrugs-10-02181">42</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Apratoxins B-C</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">KB oral epidermoid cancer and LoVo colon cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B40-marinedrugs-10-02181">40</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Apratoxin D</td>
              <td align="center" valign="middle"><italic>Lyngbya majuscula </italic>and <italic>Lyngbya sordida</italic></td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B26-marinedrugs-10-02181">26</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Apratoxin E</td>
              <td align="center" valign="middle">
                <italic>Lyngbya bouilloni</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">U2OS osteosarcoma, HT29 colon adenocarcinoma and HeLa epithelial carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B42-marinedrugs-10-02181">42</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Apratoxins F and G</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Lyngbya bouilloni</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B43-marinedrugs-10-02181">43</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Hemocytometer counting</td>
              <td align="center" valign="middle">HCT-116 colorectal cancer cells</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B43-marinedrugs-10-02181">43</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Aurilide B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung tumor</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B24-marinedrugs-10-02181">24</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Aurilide C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">NCI-H460 lung tumor</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B24-marinedrugs-10-02181">24</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Belamide A</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Linear tetrapeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">HCT-116 colon cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B8-marinedrugs-10-02181">8</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Bisebromoamide</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Peptide</td>
              <td align="center" valign="middle">SRB</td>
              <td align="center" valign="middle">HeLa S<sub>3 </sub>epithelial carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B44-marinedrugs-10-02181">44</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Biselyngbyaside</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Glicomacrolide</td>
              <td align="center" valign="middle">SRB</td>
              <td align="center" valign="middle">HeLa S3 epithelial carcinoma, SNB-78 central nervous system cancer and NCI H522 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B15-marinedrugs-10-02181">15</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Calothrixin A</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Calothrix</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Pentacyclic indolophenanthridine</td>
              <td align="center" valign="middle"><sup>3</sup>H-thymidine incorporation</td>
              <td align="center" valign="middle">HeLa epithelial carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B45-marinedrugs-10-02181">45</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">Leukemia CEM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B46-marinedrugs-10-02181">46</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Calothrixin B</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Calothrix</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Pentacyclic indolophenanthridine</td>
              <td rowspan="2" align="center" valign="middle">MTT </td>
              <td align="center" valign="middle">HeLa epithelial carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B47-marinedrugs-10-02181">47</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Leukemia CEM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B46-marinedrugs-10-02181">46</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Caylobolide A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Macrolactone</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">HCT-116 colon tumor</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B48-marinedrugs-10-02181">48</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Caylobolide B</td>
              <td align="center" valign="middle"><italic>Phormidium </italic>spp<italic>.</italic></td>
              <td align="center" valign="middle">Macrolactone</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">HT29 colorectal adenocarcinoma and HeLa cervical carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B16-marinedrugs-10-02181">16</xref>]</td>
             </tr>
            <tr>
              <td align="center" valign="middle">Coibamide A</td>
              <td align="center" valign="middle"><italic>Leptolyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">Lung cancer NCI-H460, breast cancer MDA-MB-231, melanoma LOX IMVI, leukemia HL-60 and astrocytoma SNB75</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B49-marinedrugs-10-02181">49</xref>]</td>
             </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Cryptophycin 1</td>
              <td rowspan="2" align="center" valign="middle"><italic>Nostoc </italic>spp<italic>.</italic></td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Cell morphology examination</td>
              <td align="center" valign="middle">MDA-MB-435 mammary adenocarcinoma and SKOV3 ovarian carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B50-marinedrugs-10-02181">50</xref>]</td>
             </tr>
            <tr>
              <td align="center" valign="middle">AlamarBlue dye reduction</td>
              <td align="center" valign="middle">Leukemia U937, CCRF-CEM and HL-60, colon carcinoma HT-29, GC3 and Caco-2, mammary carcinoma MCF-7 and MDA-MB-231 and cervical carcinoma HeLa</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B51-marinedrugs-10-02181">51</xref>]</td>
              
            </tr>
            <tr>
              <td rowspan="5" align="center" valign="middle">Dolastatin 10</td>
              <td rowspan="5" align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td rowspan="5" align="center" valign="middle">Linear Pentapeptide</td>
              <td rowspan="3" align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">Lung A549 carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Human lung cancer cells: NCI-H69, -H82, -H446 and -H510</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B53-marinedrugs-10-02181">53</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Human DU-145 prostate cancer cell line</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B54-marinedrugs-10-02181">54</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">[3H] Thymidine</td>
              <td align="center" valign="middle">Several lymphoma cell lines</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B55-marinedrugs-10-02181">55</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Trypan blue dye</td>
              <td align="center" valign="middle">Reh lymphoblastic leukemia</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B56-marinedrugs-10-02181">56</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Dolastatin 12</td>
              <td align="center" valign="middle"><italic>Leptolyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">A549 lung carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Dragonamide</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">A-549 lung epithelial adenocarcinoma, HT-29 colon adenocarcinoma and MEL-28 melanoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B57-marinedrugs-10-02181">57</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Ethyl Tumonoate A</td>
              <td align="center" valign="middle">
                <italic>Oscillatoria margaritifera</italic>
              </td>
              <td align="center" valign="middle">Peptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B58-marinedrugs-10-02181">58</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Hoiamide A</td>
              <td align="center" valign="middle">Assemblage of 
              <italic>Lyngbya majuscule and Phormidium </italic>gracile</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B59-marinedrugs-10-02181">59</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Hoiamide B</td>
              <td align="center" valign="middle">Cyanobacterial sample</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B59-marinedrugs-10-02181">59</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Homodolastatin 16</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">WHCO1 and WHCO6 esophageal cancer and ME180 cervical cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B60-marinedrugs-10-02181">60</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Isomalyngamide A and A-1</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Fatty acid amides</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">Breast cancer MCF-7 and MDA-MB-231</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B13-marinedrugs-10-02181">13</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Jamaicamides A-C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Polyketide-Peptides</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B61-marinedrugs-10-02181">61</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Kalkitoxin</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Trypan blue dye</td>
              <td align="center" valign="middle">HCT-116 colon</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B62-marinedrugs-10-02181">62</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Lagunamide C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">Lung adenocarcinoma A549, cancer prostate PC3, ileocecal colorectal cancer HCT8 and ovary cancer SK-OV</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B63-marinedrugs-10-02181">63</xref>]</td>
              
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Largazole</td>
              <td rowspan="2" align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptide</td>
              <td rowspan="2" align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">MDA-MB-23I breast cancer and U2OS osteosarcoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B64-marinedrugs-10-02181">64</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">A549 lung cancer and HCT-116 colorectal carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B65-marinedrugs-10-02181">65</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyabellin A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB nasopharyngeal carcinoma and LoVo colon adenocarcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B66-marinedrugs-10-02181">66</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyaloside</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Glicomacrolide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB nasopharyngeal carcinoma and LoVo colon adenocarcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B67-marinedrugs-10-02181">67</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Majusculamide C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">Ovarian carcinoma OVCAR-3, kidney cancer A498, lung cancer NCI-H460, colorectal cancer KM20L2 and glioblastoma SF-295</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B68-marinedrugs-10-02181">68</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Malevamide D</td>
              <td align="center" valign="middle">
                <italic>Symploca hydnoides</italic>
              </td>
              <td align="center" valign="middle">Peptide ester</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">Lung cancer A-549, colon cancer HT-29 and melanoma MEL-28.</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B69-marinedrugs-10-02181">69</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Malyngamide 2</td>
              <td align="center" valign="middle">
                <italic>Lyngbya sordida</italic>
              </td>
              <td align="center" valign="middle">Fatty acid amine</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B23-marinedrugs-10-02181">23</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Malyngamide C, J and K</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Fatty acid amines</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B70-marinedrugs-10-02181">70</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Malyngolide dimmer</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclodepside</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B71-marinedrugs-10-02181">71</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Nostocyclopeptide A1 and A2</td>
              <td align="center" valign="middle"><italic>Nostoc </italic>sp.</td>
              <td align="center" valign="middle">Cyclic heptapeptides</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB oral epidermoid cancer and LoVo colon cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B72-marinedrugs-10-02181">72</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Obyanamide</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB oral epidermoid cancer and LoVo colon cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B73-marinedrugs-10-02181">73</xref>]</td>
              
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Palauamide</td>
              <td rowspan="2" align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptide</td>
              <td rowspan="2" align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">Cervical carcinoma HeLa, lung adenocarcinoma A549 and gastrocarcinoma BGC</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B74-marinedrugs-10-02181">74</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">KB oral epidermoid cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B75-marinedrugs-10-02181">75</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Palmyramide A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B76-marinedrugs-10-02181">76</xref>]</td>
              
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Pitipeptolides A-B</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">LoVo colon cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B77-marinedrugs-10-02181">77</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">HT29 colon adenocarcinoma and MCF-7 breast cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B17-marinedrugs-10-02181">17</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Pitipeptolide C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">HT29 colon adenocarcinoma and MCF-7 breast cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B17-marinedrugs-10-02181">17</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Pitiprolamide</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">HCT116 colorectal carcinoma and MCF7 breast adenocarcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B78-marinedrugs-10-02181">78</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Pseudodysidenin</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">A-549 lung adenocarcinoma, HT-29 colon adenocarcinoma and MEL-28 melanoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B57-marinedrugs-10-02181">57</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Somocystinamide A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">XTT</td>
              <td align="center" valign="middle">Jurkat and CEM leukemia, A549 lung carcinoma, Molt4 T leukemia, M21 melanoma and U266 myeloma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B79-marinedrugs-10-02181">79</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Symplocamide</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Cyclic peptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B27-marinedrugs-10-02181">27</xref>]</td>
              
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Symplostatin 1</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Symploca hydnoides</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Linear Pentapeptide</td>
              <td rowspan="2" align="center" valign="middle">SRB</td>
              <td align="center" valign="middle">MDA-MB-435 breast carcinoma and NCI/ADR ovarian carcinoma</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Epidermoid carcinoma cell line</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B80-marinedrugs-10-02181">80</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Tasiamide</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Cyclic peptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB oral epidermoid cancer and LoVo colon cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B81-marinedrugs-10-02181">81</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Tasiamide B</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Peptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB oral epidermoid cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B82-marinedrugs-10-02181">82</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Tasipeptins A-B</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB oral epidermoid cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B83-marinedrugs-10-02181">83</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Ulongapeptin</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Non-specified</td>
              <td align="center" valign="middle">KB oral epidermoid cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B84-marinedrugs-10-02181">84</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Veraguamides A-G</td>
              <td align="center" valign="middle">
                <italic>Symploca cf. hydnoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B85-marinedrugs-10-02181">85</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Wewakazole</td>
              <td align="center" valign="middle">
                <italic>Lyngbya sordida</italic>
              </td>
              <td align="center" valign="middle">Cyclic dodecapeptide</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B23-marinedrugs-10-02181">23</xref>]</td>
              
            </tr>
            <tr>
              <td align="center" valign="middle">Wewakpeptins</td>
              <td align="center" valign="middle">
                <italic>Lyngbya semiplena</italic>
              </td>
              <td align="center" valign="middle">Depsipeptides</td>
              <td align="center" valign="middle">MTT</td>
              <td align="center" valign="middle">H-460 lung cancer</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B11-marinedrugs-10-02181">11</xref>]</td>
              
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
        <fn>
         <p>MTT: 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2<italic>H</italic>-tetrazolium-5-carboxanilide; SBR: Sulforhodamine B.</p>
        </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="marinedrugs-10-02181-t002" position="float">
        <object-id pub-id-type="pii">marinedrugs-10-02181-t002_Table 2</object-id>
        <label>Table 2</label>
        <caption>
          <p>Relevant anticancer cell effects induced by marine cyanobacteria compounds.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle">Compound</th>
              <th align="center" valign="middle">Source</th>
              <th align="center" valign="middle">Class of compound</th>
              <th align="center" valign="middle">Model tested</th>
              <th align="center" valign="middle">Cell effect</th>
              <th align="center" valign="middle">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">Alotamide</td>
              <td align="center" valign="middle">
                <italic>Lyngbya bouillonii</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Murine cerebrocortical neurons</td>
              <td align="center" valign="middle">Calcium inﬂux promotion</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B12-marinedrugs-10-02181">12</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Ankaraholide A</td>
              <td align="center" valign="middle">
                <italic>Geitlerinema</italic>
              </td>
              <td align="center" valign="middle">Glycosilated swinholide</td>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Loss of filamentous (F)-actin</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B14-marinedrugs-10-02181">14</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Antillatoxin</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Primary rat cerebellar granule cells</td>
              <td rowspan="2" align="center" valign="middle">Voltage-gated sodium channel activation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B86-marinedrugs-10-02181">86</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">CHL 1610 Chinese hamster lung cells</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B87-marinedrugs-10-02181">87</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Antillatoxin B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">neuro-2a mouse neuroblastoma cells</td>
              <td align="center" valign="middle">Sodium channel activation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B10-marinedrugs-10-02181">10</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Apratoxin A</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Human HeLa cervical carcinoma cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B88-marinedrugs-10-02181">88</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human U2OS osteosarcoma cells</td>
              <td align="center" valign="middle">Secretory pathway inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B89-marinedrugs-10-02181">89</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Aurilide B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Microfilament disruption</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B24-marinedrugs-10-02181">24</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Belamide A</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Linear tetrapeptide</td>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Microtubule disruption</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B8-marinedrugs-10-02181">8</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Bisebromoamide</td>
              <td rowspan="2" align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td rowspan="2" align="center" valign="middle">Peptide</td>
              <td align="center" valign="middle">Human HeLa epithelial carcinoma cells</td>
              <td align="center" valign="middle">Actin filaments stabilization</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B90-marinedrugs-10-02181">90</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Normal rat kidney cells extracellular signal regulated protein kinase</td>
              <td align="center" valign="middle">Protein kinase inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B44-marinedrugs-10-02181">44</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Bouillomides A-B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya bouillonii</italic>
              </td>
              <td align="center" valign="middle">Depsipeptides</td>
              <td align="center" valign="middle">Elastase and chymotrypsin</td>
              <td align="center" valign="middle">Serine proteases inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B91-marinedrugs-10-02181">91</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Calothrixin A</td>
              <td align="center" valign="middle">
                <italic>Calothrix</italic>
              </td>
              <td align="center" valign="middle">Pentacyclic indolophenanthridine</td>
              <td align="center" valign="middle">Human leukemia CEM cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B46-marinedrugs-10-02181">46</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Calothrixin B</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Calothrix</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Pentacyclic indolophenanthridine</td>
              <td align="center" valign="middle">Human HeLa epithelial carcinoma cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B45-marinedrugs-10-02181">45</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human HeLa epithelial carcinoma cells</td>
              <td align="center" valign="middle">Oxidative stress induction</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B45-marinedrugs-10-02181">45</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Coibamide A</td>
              <td align="center" valign="middle"><italic>Leptolyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Human NCI-H460 lung cancer cell line</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B49-marinedrugs-10-02181">49</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Cryptophycin 1</td>
              <td rowspan="2" align="center" valign="middle"><italic>Nostoc </italic>spp<italic>.</italic></td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Human MDA-MB-435 mammary adenocarcinoma and SKOV3 ovarian carcinoma cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B50-marinedrugs-10-02181">50</xref>] </td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human MDA-MB-435 mammary adenocarcinoma</td>
              <td align="center" valign="middle">Caspase-3 protein activation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B50-marinedrugs-10-02181">50</xref>] </td>
            </tr>
            <tr>
              <td rowspan="4" align="center" valign="middle">Curacin A</td>
              <td rowspan="4" align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td rowspan="4" align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Tubulin</td>
              <td align="center" valign="middle">Tubulin polymerization inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B92-marinedrugs-10-02181">92</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human A549 lung carcinoma cells</td>
              <td align="center" valign="middle">Bad protein levels increase</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human A549 lung carcinoma cells</td>
              <td align="center" valign="middle">Caspase-3 protein activation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Bovine β-tubulin</td>
              <td align="center" valign="middle">Tubulin polymerization inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B93-marinedrugs-10-02181">93</xref>]</td>
            </tr>
            <tr>
              <td rowspan="4" align="center" valign="middle">Dolastatin 10</td>
              <td rowspan="4" align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td rowspan="4" align="center" valign="middle">Linear Pentapeptide</td>
              <td align="center" valign="middle">Human Reh lymphoblastic leukemia cells</td>
              <td align="center" valign="middle">Bcl-2 protein reduction</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B56-marinedrugs-10-02181">56</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human lung cancer cells: NCI-H69 and -H510</td>
              <td align="center" valign="middle">Bcl-2 protein phosphorylation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B53-marinedrugs-10-02181">53</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human A549 lung carcinoma cells</td>
              <td align="center" valign="middle">Bad protein levels increase</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human A549 lung carcinoma cells</td>
              <td align="center" valign="middle">Caspase-3 protein activation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Dolastatin 12</td>
              <td align="center" valign="middle"><italic>Leptolyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Microfilament disruptor</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B94-marinedrugs-10-02181">94</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Grassystatin A-B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Linear depsipeptides</td>
              <td align="center" valign="middle">Cathepsins D and E</td>
              <td align="center" valign="middle">Proteases inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B95-marinedrugs-10-02181">95</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Hectochlorin</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Human CA46 Burkitt lymphoma cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B18-marinedrugs-10-02181">18</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Hermitamides A-B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Human HEK embryonic kidney cells</td>
              <td align="center" valign="middle">Voltage-gated sodium channel inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B96-marinedrugs-10-02181">96</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Hoiamide A</td>
              <td align="center" valign="middle">Assemblage of <italic>Lyngbya majuscule </italic>and <italic>Phormidium gracile</italic></td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Primary cultures of neocortical neurons from embryonic mice</td>
              <td align="center" valign="middle">Sodium channel activation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B59-marinedrugs-10-02181">59</xref>,<xref ref-type="bibr" rid="B97-marinedrugs-10-02181">97</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Hoiamide B</td>
              <td align="center" valign="middle">Cyanobacterial sample</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Primary cultures of neocortical neurons from embryonic mice</td>
              <td align="center" valign="middle">Sodium influx stimulation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B59-marinedrugs-10-02181">59</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Kalkitoxin</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Lipopeptide</td>
              <td align="center" valign="middle">Primary rat cerebellar granule neuron cultures</td>
              <td align="center" valign="middle">Calcium influx inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B98-marinedrugs-10-02181">98</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Kempopeptin A</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Bovine pancreatic α-chymotrypsin, porcine pancreatic elastase</td>
              <td align="center" valign="middle">Serine Protease Inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Kempopeptin B</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Trypsin</td>
              <td align="center" valign="middle">Serine Protease Inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamides A-C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">Porcine pancreatic elastase</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B100-marinedrugs-10-02181">100</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamides D-G</td>
              <td align="center" valign="middle"><italic>Oscillatoria </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">α-chymotrypsin</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B101-marinedrugs-10-02181">101</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Lyngbyabellin A</td>
              <td rowspan="2" align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td rowspan="2" align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Human CA46 Burkitt lymphoma cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B18-marinedrugs-10-02181">18</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Microfilament disruption</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B66-marinedrugs-10-02181">66</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyabellin B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Human CA46 Burkitt lymphoma cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B18-marinedrugs-10-02181">18</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 1</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Microfilament disruption</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B94-marinedrugs-10-02181">94</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 4</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Bovine pancreatic α-chymotrypsin and porcine pancreatic elastase</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B102-marinedrugs-10-02181">102</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 5-7</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>spp<italic>.</italic></td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">Porcine pancreatic elastase</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B103-marinedrugs-10-02181">103</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 8-10</td>
              <td align="center" valign="middle">
                <italic>Lyngbya semiplena</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">Porcine pancreatic elastase</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B104-marinedrugs-10-02181">104</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Malevamide E</td>
              <td align="center" valign="middle">
                <italic>Symploca laete-viridis</italic>
              </td>
              <td align="center" valign="middle">Depsipeptide</td>
              <td align="center" valign="middle">Human HEK embryonic kidney cells</td>
              <td align="center" valign="middle">Calcium influx inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B105-marinedrugs-10-02181">105</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Molassamide</td>
              <td align="center" valign="middle">
                <italic>Dichothrix utahensis</italic>
              </td>
              <td align="center" valign="middle">Depsipeptide</td>
              <td align="center" valign="middle">Bovine pancreatic α-chymotrypsin and porcine pancreatic elastase</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B106-marinedrugs-10-02181">106</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Palmyramide A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Mouse neuroblastoma neuro-2a cells</td>
              <td align="center" valign="middle">Sodium channel inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B76-marinedrugs-10-02181">76</xref>]</td>
            </tr>
            <tr>
              <td rowspan="2" align="center" valign="middle">Palmyrolide</td>
              <td rowspan="2" align="center" valign="middle">Assemblage of <italic>Leptolyngbya </italic>cf. and <italic>Oscillatoria </italic>spp<italic>.</italic></td>
              <td rowspan="2" align="center" valign="middle">Macrolide</td>
              <td align="center" valign="middle">Mouse neuroblastoma neuro-2a cells</td>
              <td align="center" valign="middle">Sodium influx inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B107-marinedrugs-10-02181">107</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Murine cerebrocortical neurons</td>
              <td align="center" valign="middle">Inhibition of calcium oscillations</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B107-marinedrugs-10-02181">107</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Pitipeptolides A and B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya majuscula</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">Elastase</td>
              <td align="center" valign="middle">Serine protease stimulation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B77-marinedrugs-10-02181">77</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Pompanopeptin A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic peptide</td>
              <td align="center" valign="middle">Porcine pancreatic trypsin</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B108-marinedrugs-10-02181">108</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Symplocamide</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Cyclic peptide</td>
              <td align="center" valign="middle">Chymotrypsin</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B27-marinedrugs-10-02181">27</xref>]</td>
            </tr>
            <tr>
              <td rowspan="4" align="center" valign="middle">Symplostatin 1</td>
              <td rowspan="4" align="center" valign="middle">
                <italic>Symploca hydnoides</italic>
              </td>
              <td rowspan="4" align="center" valign="middle">Linear Pentapeptide</td>
              <td align="center" valign="middle">Rat aorta A-10 and human HeLa cervical carcinoma cells</td>
              <td align="center" valign="middle">Cell cycle inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Microtubule depolymerization</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B109-marinedrugs-10-02181">109</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human MDA-MB-435 breast carcinoma cells</td>
              <td align="center" valign="middle">Bcl-2 phosphorylation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Human MDA-MB-435 breast carcinoma cells</td>
              <td align="center" valign="middle">Caspase-3 protein activity stimulation</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Symplostatin 3</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle"> </td>
              <td align="center" valign="middle">Rat aorta A-10 cells</td>
              <td align="center" valign="middle">Microtubule depolymerization</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B110-marinedrugs-10-02181">110</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Tiglicamides A-C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptides</td>
              <td align="center" valign="middle">Porcine pancreatic elastase</td>
              <td align="center" valign="middle">Serine protease inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B111-marinedrugs-10-02181">111</xref>]</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
     
    </sec>
    <sec>
      <title>2. Cell Cycle Arrest</title>
      <p>Cell cycle is a delicate mechanism that comprises cell growth and its division into two daughter cells. Some substances are able to disturb the normal functioning of this mechanism compromising cell viability, a consequence that can be directly related with apoptosis. A common cellular damage induced by marine cyanobacteria compounds is the disruption of microtubules and actin proteins [<xref ref-type="bibr" rid="B112-marinedrugs-10-02181">112</xref>]. As these proteins are directly involved in mitosis, alterations in the normal functioning of the cell cycle occur. The most frequent consequence is G<sub>2</sub>/M phase arrest. Cryptophycin 52, a macrocyclic depsipeptide analogue of the naturally occurring cryptophycins isolated from the marine cyanobacteria <italic>Nostoc</italic> spp. [<xref ref-type="bibr" rid="B113-marinedrugs-10-02181">113</xref>], and calothrixin A, a indolophenanthridine isolated from <italic>Calothrix</italic>, are two examples of bioactive metabolites that induced, in different human cancer cell lines, a cell cycle arrest in G<sub>2</sub>/M phase [<xref ref-type="bibr" rid="B45-marinedrugs-10-02181">45</xref>]. Dolastatins are cytotoxic peptides that were initially isolated from the sea hare <italic>Dolabella auricularia</italic> and later found to be produced by marine cyanobacterial strains [<xref ref-type="bibr" rid="B109-marinedrugs-10-02181">109</xref>]. To explore their anticancer potential, several synthetic analogues were produced. Dolastatin 10, found in <italic>Symploca</italic>, and its non-cyanobacterial analogue, dolastatin 15, were both found to induce an arrest in the same cell cycle phase, G<sub>2</sub>/M phase, inducing apoptosis [<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>,<xref ref-type="bibr" rid="B114-marinedrugs-10-02181">114</xref>]. Symplostatin 1, another analogue of dolastatin 10 and cryptophycin 1, a dolastatin 52 analogue, were also responsible for a G<sub>2</sub>/M arrest in human cancer cells and for disturbances in the formation of mitotic spindles [<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>,<xref ref-type="bibr" rid="B113-marinedrugs-10-02181">113</xref>,<xref ref-type="bibr" rid="B114-marinedrugs-10-02181">114</xref>]. Calothrixin A, beyond an arrest in G<sub>2</sub>/M phase in a leukemia cell line at 1 μM and 10 μM, is also responsible for a cumulative arrest in S phase [<xref ref-type="bibr" rid="B46-marinedrugs-10-02181">46</xref>]. Hectochlorin and lyngbyabellins are structurally related lipopeptide and cyclic depsipeptides isolated from the genus <italic>Lyngbya</italic>. Both hectochlorin and lyngbyabellin B are described to induce an arrest in G<sub>2</sub>/M phase in a human Burkitt lymphoma cell line, accompanied with a related increase in binucleated cells and an apparent thickening of the microfilaments [<xref ref-type="bibr" rid="B18-marinedrugs-10-02181">18</xref>]. Nagarajan and co-workers [<xref ref-type="bibr" rid="B115-marinedrugs-10-02181">115</xref>] suggested that the inhibition of cell cycle proliferation by lyngbyabellins is assigned to a thiazole ring and dichlorinated components (<xref ref-type="fig" rid="marinedrugs-10-02181-f001">Figure 1</xref>), once these compounds were all found to inhibit cell cycle proliferation [<xref ref-type="bibr" rid="B18-marinedrugs-10-02181">18</xref>,<xref ref-type="bibr" rid="B116-marinedrugs-10-02181">116</xref>]. </p>
      <fig id="marinedrugs-10-02181-f001" position="anchor">
        <label>Figure 1</label>
        <caption>
          <p>Chemical structures of the marine cyanobacterial secondary metabolites hectochlorin and lyngbyabellins A and B.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="marinedrugs-10-02181-g001.tif"/>
      </fig>
      <p>Besides G2/M phase arrest effects in G1 phase are also described. Khan and co-workers [<xref ref-type="bibr" rid="B46-marinedrugs-10-02181">46</xref>] reported a G<sub>1</sub> phase arrest after treatment with a low concentration (0.1 μM) of calothrixin B. The same effect was demonstrated by Ma <italic>et al</italic>. [<xref ref-type="bibr" rid="B88-marinedrugs-10-02181">88</xref>] in a cervical carcinoma cell line treated with the cyclic depsipeptide apratoxin A (50 nM). Coibamide, a potent cytotoxic cyclic depsipeptide, founded in a Panamanian <italic>Leptolyngbya </italic>sp., was also described as capable to cause a significant dose dependent increase in the number of cells in G<sub>1</sub> phase of the cell cycle [<xref ref-type="bibr" rid="B49-marinedrugs-10-02181">49</xref>].</p>
    </sec>
    <sec>
      <title>3. Mitochondrial Dysfunctions and Oxidative Damage</title>
      <p>Mitochondria have essential functions in aerobic cells, and interferences in its normal behavior are crucial to determine cell fate [<xref ref-type="bibr" rid="B117-marinedrugs-10-02181">117</xref>]. A dysfunction in these organelles imbalances the cell redox potential, inducing damages in cell components that can lead, in the cases that pro-survival mechanisms fail, to apoptosis [<xref ref-type="bibr" rid="B118-marinedrugs-10-02181">118</xref>]. To the best of our knowledge, no study relating marine cyanobacterial natural products with mitochondrial dysfunctions has been done. However aurilide, a cyclodepsipeptide isolated from the sea hare <italic>Dolabella auricularia</italic> and related with the marine cyanobacterial aurilides A and B, is described to induce a dysfunction in mitochondria. HeLa cells, when treated with this metabolite exhibited mitochondria fragmentation, visible by MitoTracker Red staining [<xref ref-type="bibr" rid="B119-marinedrugs-10-02181">119</xref>]. </p>
      <p>Oxidative stress is a cell condition that can be triggered by mitochondrial disorders. It can occur due to an overproduction of reactive oxygen species (ROS) or to a decrease in antioxidant levels [<xref ref-type="bibr" rid="B120-marinedrugs-10-02181">120</xref>]. Calothrixin A is described as an oxidative stress inducer in Jurkat human T cells, since they show an increase on intracellular ROS content after treatment with that molecule [<xref ref-type="bibr" rid="B45-marinedrugs-10-02181">45</xref>]. DNA damage is also a consequence directly associated to the oxidative stress, and it is commonly observed as a result of exposure to cyanobacterial secondary metabolites. As expected, besides an increase in ROS, calothrixin A foments DNA fragmentation [<xref ref-type="bibr" rid="B45-marinedrugs-10-02181">45</xref>]. DNA fragmentation is the most common DNA damage observed. Dolastatin 10 induced DNA damage on several human lymphoma cell lines [<xref ref-type="bibr" rid="B55-marinedrugs-10-02181">55</xref>] and on lung cancer cells [<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]. Cryptophycins 1 and 52 are also metabolites that were found to induce DNA fragmentation [<xref ref-type="bibr" rid="B50-marinedrugs-10-02181">50</xref>,<xref ref-type="bibr" rid="B113-marinedrugs-10-02181">113</xref>]. </p>
      <p>External nuclei alterations can be also a consequence of oxidative stress. Binucleated cells are frequently observed as a response to cyanobacterial products, as swinholide A, isolated from cyanobacterial samples of <italic>Symploca </italic>cf. sp. [<xref ref-type="bibr" rid="B14-marinedrugs-10-02181">14</xref>] or lyngbyabellin [<xref ref-type="bibr" rid="B116-marinedrugs-10-02181">116</xref>]. Symplostatin 1 was found to induce an abnormal nuclear convolution in a rat aorta cell line, leading to the breakdown of nucleus and the formation of numerous micronuclei [<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>].</p>
      <p>To counterbalance the deleterious effects of ROS, cells developed a complex antioxidant system. The antioxidant enzymes, like superoxide dismutase (SOD), catalase, glutathione-<italic>S</italic>-transferase (GST) and several peroxidases, constitute the front line, with important scavenging functions. Some other molecules, with low molecular weight, have crucial roles, such as glutathione, ascorbate or phenolic compounds [<xref ref-type="bibr" rid="B121-marinedrugs-10-02181">121</xref>]. The capacity of marine cyanobacterial natural products to interfere with the antioxidant system of human cells is not well elucidated. Evidences indicate that pigments are the compounds with higher antioxidant activity. Carotenoids isolated from the marine <italic>Trichodesmium</italic> are responsible for an antioxidative protection, observed with ferric reducing/antioxidant power assay [<xref ref-type="bibr" rid="B122-marinedrugs-10-02181">122</xref>]. In the same study, extracts from marine strains of <italic>Anabaena</italic>, <italic>Cyanothece</italic>, <italic>Prochlorothrix </italic>and <italic>Synechococcus</italic> showed antioxidant properties, but mainly in the protein extract [<xref ref-type="bibr" rid="B122-marinedrugs-10-02181">122</xref>]. Also the major phycobiliprotein, c-phycocyanin, from both <italic>Lyngbya</italic> and <italic>Phormidium</italic>, is capable to scavenge ROS, in particular peroxyl and hydroxyl radicals [<xref ref-type="bibr" rid="B123-marinedrugs-10-02181">123</xref>]. It was also suggested that this antioxidant capacity is resultant from the covalent linked tetrapyrole chromophore with phycocyanobilin [<xref ref-type="bibr" rid="B123-marinedrugs-10-02181">123</xref>]. </p>
    </sec>
    <sec>
      <title>4. Alterations in Caspase Cascade</title>
      <p>Caspases are a family of cysteine aspartate proteases that act as the central executers of apoptosis. They are synthesized as inactive zymogens, which are activated after proteolytic cleavage [<xref ref-type="bibr" rid="B124-marinedrugs-10-02181">124</xref>]. According to their point of entrance into apoptotic process, caspases can be classified as initiators or effectors. Initiator caspases, that include -8, -9, and -10, activate the downstream effectors caspases, -3, -6 and -7, in a cascade of events that triggers a controlled and programmed cell death [<xref ref-type="bibr" rid="B125-marinedrugs-10-02181">125</xref>].</p>
      <p>Marine cyanobacteria produce several compounds that are capable to induce alterations on caspases as a pathway to induce cell death. Several marine benthic cyanobacterial extracts showed to induce apoptosis partially dependent of protein caspases. Cells overexpressing LEDGF/p75, an inhibitor of cell death dependent of caspases, showed an increase in just a few number of apoptotic cells after treatment, when compared with the control [<xref ref-type="bibr" rid="B39-marinedrugs-10-02181">39</xref>].</p>
      <p>Caspase-3 is the most studied caspase concerning to apoptosis induced by natural products. The activity of caspase-3 protein is increased after exposure to symplostatin 1 [<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>] and to the glicomacrolide biselyngbyaside [<xref ref-type="bibr" rid="B38-marinedrugs-10-02181">38</xref>]. Also cryptophycin 1 is described to induce apoptosis in a human ovarian carcinoma cell line, initiating the caspases cascade through caspase-3 activation [<xref ref-type="bibr" rid="B50-marinedrugs-10-02181">50</xref>]. The cleavage, and therefore the activation, of caspase-3 were still previously observed as a response to dolastatins 10 and 15 and to the lipopeptide curacin A [<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>].</p>
      <p>Cryptophycin 52 induced an apoptosis dependent on both caspase-3 and caspase-1 activation [<xref ref-type="bibr" rid="B113-marinedrugs-10-02181">113</xref>]. Another study [<xref ref-type="bibr" rid="B79-marinedrugs-10-02181">79</xref>] also reported that apoptosis induced by somocystinamide A, a lipopeptide from <italic>Lyngbya majuscula</italic>, occurs in a caspase-8 dependent manner, since it was observed an inhibition of tumor growth selectively in the caspase-8-expressing neuroblastoma cells, when compared with cells lacking the protein.</p>
    </sec>
    <sec>
      <title>5. Non-Caspases Proteases Involvement</title>
      <p>Although caspases have a central role in the apoptotic cell death developing, it is described that the process often continues after an inhibition of this proteins [<xref ref-type="bibr" rid="B126-marinedrugs-10-02181">126</xref>,<xref ref-type="bibr" rid="B127-marinedrugs-10-02181">127</xref>]. This finding suggests the implication of other executors, which promote apoptosis in the absence of caspases. It was already proposed that some other proteases, capable to support apoptosis, have caspases amplification and assistance functions [<xref ref-type="bibr" rid="B128-marinedrugs-10-02181">128</xref>]. </p>
      <p>Proteases are involved in the irreversibly hydrolysis of the peptide bonds in proteins, an important post-translational modification. These proteolytic enzymes are important for the control of a large number of key physiological processes, including apoptosis [<xref ref-type="bibr" rid="B129-marinedrugs-10-02181">129</xref>]. Apoptotic cell death induced by intracellular proteolysis of some serine proteases is already described [<xref ref-type="bibr" rid="B130-marinedrugs-10-02181">130</xref>]. Several cyanobacterial compounds have been described to interfere with the normal functioning of serine proteases, mainly the pancreatic elastase, chymotrypsin and trypsin, as is resumed in <xref ref-type="table" rid="marinedrugs-10-02181-t003">Table 3</xref>. Symplocamide A was described to inhibit chymotrypsin with an IC<sub>50</sub> of 0.38 μM, with trypsin being also affected but with an IC<sub>50</sub> of 80.2 μM, a difference greater than 200-fold [<xref ref-type="bibr" rid="B27-marinedrugs-10-02181">27</xref>]. The authors suggested that, to inhibit trypsin under 10 μM, a basic aminoacid residue between treonine (Thr) and 3-amino-6-hydroxy-2-piperidone (Ahp) is needed. A hydrophobic and neutral residue in this position confers to the compound a preference for chymotrypsin. Kempopeptins A and B are other two cyclodepsipeptides isolated from a Floridian collection of a marine <italic>Lyngbya </italic>sp. that reveal a strong potency to inhibit proteases activity [<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>]. Kempopeptin B, with a leucine (Leu) residue between Thr and Ahp (<xref ref-type="fig" rid="marinedrugs-10-02181-f002">Figure 2</xref>), only inhibit trypsin activity (IC<sub>50</sub> = 8.4 μM), but kempopeptin A, with a lysine (Lys) in the same position, inhibit both elastase (IC<sub>50</sub> = 0.32 μM) and chymotrypsin (IC<sub>50</sub> = 2.6 μM). Bouillomides A and B, two depsipeptides isolated from <italic>Lyngbya bouillonii</italic> and molassamide, a depsipeptide from <italic>Dichothrix utahensis</italic>, all dolastatin 13 analogues, contain 2-aminobutyric acid (Abu) between Thr and Ahp. As expected, these metabolites are chymotrypsin inhibitors [<xref ref-type="bibr" rid="B91-marinedrugs-10-02181">91</xref>,<xref ref-type="bibr" rid="B106-marinedrugs-10-02181">106</xref>]. Largamides are another family of cyclic peptides isolated from <italic>Lyngbya confervoides</italic>. Largamides D and E, with a Leu residue between Thr and Ahp, and largamides F and G, with a tyrosine (Tyr) in the same position, also inhibited chymotrypsin with IC<sub>50</sub> range from 4.0 to 25.0 μM [<xref ref-type="bibr" rid="B101-marinedrugs-10-02181">101</xref>]. </p>
      
      
      <p>Pompanopeptin A, a cyclic peptide isolated from the <italic>Lyngbya confervoides</italic> and kempopeptin B, contain arginine (Arg) and lysine (Lys), respectively, between Thr and Ahp. These basic residues give to the compounds the capacity to inhibit trypsin, pompanopeptin with an IC<sub>50</sub> of 2.4 μM and kempopeptin with 8.4 μM [<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>,<xref ref-type="bibr" rid="B108-marinedrugs-10-02181">108</xref>].</p>
      <p>Ahp residue-containing natural products are responsible for the inhibition of elastase [<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>]. Lyngbyastatins 4–10, a group of compounds that contain the Ahp residue, were all described as elastase inhibitors [<xref ref-type="bibr" rid="B102-marinedrugs-10-02181">102</xref>,<xref ref-type="bibr" rid="B103-marinedrugs-10-02181">103</xref>,<xref ref-type="bibr" rid="B104-marinedrugs-10-02181">104</xref>] with an IC<sub>50</sub> range from 0.03 (lyngbyastatin 4) to 210 μM (lyngbyastatin 9). Lyngbyastatins are also strong chymotrypsin inhibitors, but with less potency than elastase, IC<sub>50</sub> = 0.3 μM [<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>]. The same profile is verified with the depsipeptide molassamide witch contains the Ahp residue, which is capable to inhibit the elastase activity [<xref ref-type="bibr" rid="B106-marinedrugs-10-02181">106</xref>]. Largamides A–C and tiglicamides A–C, depsipeptides isolated from <italic>Lyngbya confervoides</italic> are non-containing Ahp natural compounds. However, these products were all responsible for an elastase enzyme inhibition [<xref ref-type="bibr" rid="B100-marinedrugs-10-02181">100</xref>,<xref ref-type="bibr" rid="B111-marinedrugs-10-02181">111</xref>].</p>
      <table-wrap id="marinedrugs-10-02181-t003" position="float">
        <object-id pub-id-type="pii">marinedrugs-10-02181-t003_Table 3</object-id>
        <label>Table 3</label>
        <caption>
          <p>Marine cyanobacteria natural products with an inhibitory effect in serine proteases.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th rowspan="2" align="center" valign="middle">Compound</th>
              <th rowspan="2" align="center" valign="middle">Source</th>
              <th rowspan="2" align="center" valign="middle">Class of compound</th>
              <th colspan="3" align="center" valign="middle">Serine protease inhibition</th>
              <th rowspan="2" align="center" valign="middle">Reference</th>
            </tr>
            <tr>
              <th align="center" valign="middle">Elastase</th>
              <th align="center" valign="middle">Chymotripsin</th>
              <th align="center" valign="middle">Thrypsin</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">Bouillomide A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya bouillonii</italic>
              </td>
              <td align="center" valign="middle">Depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 1.9 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.17 μM</td>
              <td align="center" valign="middle">No inhibition at 100 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B91-marinedrugs-10-02181">91</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Bouillomide B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya bouillonii</italic>
              </td>
              <td align="center" valign="middle">Depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 1.0 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 9.3 μM</td>
              <td align="center" valign="middle">No inhibition at 100 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B91-marinedrugs-10-02181">91</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Kempopeptin A</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.32 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 2.6 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> &gt; 67 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Kempopeptin B</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> &gt; 67 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> &gt; 67 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 8.4 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B99-marinedrugs-10-02181">99</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamide A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 1.41 μM</td>
              <td align="center" valign="middle">No inhibition at 50 μM</td>
              <td align="center" valign="middle">No inhibition at 50 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B100-marinedrugs-10-02181">100</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamide B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.53 μM</td>
              <td align="center" valign="middle">No inhibition at 50 μM</td>
              <td align="center" valign="middle">No inhibition at 50 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B100-marinedrugs-10-02181">100</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamide C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 1.15 μM</td>
              <td align="center" valign="middle">No inhibition at 50 μM</td>
              <td align="center" valign="middle">No inhibition at 50 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B100-marinedrugs-10-02181">100</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamide D</td>
              <td align="center" valign="middle"><italic>Oscillatoria </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 10.0 μM</td>
              <td align="center" valign="middle">No inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B101-marinedrugs-10-02181">101</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamide E</td>
              <td align="center" valign="middle"><italic>Oscillatoria </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 10.0 μM</td>
              <td align="center" valign="middle">No inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B101-marinedrugs-10-02181">101</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamide F</td>
              <td align="center" valign="middle"><italic>Oscillatoria </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 4.0 μM</td>
              <td align="center" valign="middle">No inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B101-marinedrugs-10-02181">101</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Largamide G</td>
              <td align="center" valign="middle"><italic>Oscillatoria </italic>sp.</td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 25.0 μM</td>
              <td align="center" valign="middle">No inhibition</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B101-marinedrugs-10-02181">101</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 4</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.03 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.30 μM</td>
              <td align="center" valign="middle">No inhibition at 30 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B102-marinedrugs-10-02181">102</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 5</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>spp<italic>.</italic></td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 3.2 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 2.8 μM</td>
              <td align="center" valign="middle">No inhibition at 30 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B103-marinedrugs-10-02181">103</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 6</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>spp<italic>.</italic></td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 2.0 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 2.5 μM</td>
              <td align="center" valign="middle">No inhibition at 30 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B103-marinedrugs-10-02181">103</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 7</td>
              <td align="center" valign="middle"><italic>Lyngbya </italic>spp<italic>.</italic></td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 3.3 μMIC<sub>50</sub> = 0.47 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 2.5 μM</td>
              <td align="center" valign="middle">No inhibition at 30 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B103-marinedrugs-10-02181">103</xref>,<xref ref-type="bibr" rid="B104-marinedrugs-10-02181">104</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 8</td>
              <td align="center" valign="middle">
                <italic>Lyngbya semiplena</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.12 μM</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B104-marinedrugs-10-02181">104</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 9</td>
              <td align="center" valign="middle">
                <italic>Lyngbya semiplena</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.21 μM</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B104-marinedrugs-10-02181">104</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Lyngbyastatin 10</td>
              <td align="center" valign="middle">
                <italic>Lyngbya semiplena</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.12 μM</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B104-marinedrugs-10-02181">104</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Molassamide</td>
              <td align="center" valign="middle">
                <italic>Dichothrix utahensis</italic>
              </td>
              <td align="center" valign="middle">Depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.032 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.234 μM</td>
              <td align="center" valign="middle">No inhibition at 10 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B106-marinedrugs-10-02181">106</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Pompanopeptin A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic peptide</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 2.4 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B108-marinedrugs-10-02181">108</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Symplocamide A</td>
              <td align="center" valign="middle"><italic>Symploca </italic>sp.</td>
              <td align="center" valign="middle">Cyclic peptide</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 0.38 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 80.2 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B27-marinedrugs-10-02181">27</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Somamide B</td>
              <td align="center" valign="middle"><italic>Lyngbya majuscula </italic>and<italic> Schizothrix</italic> assemblage</td>
              <td align="center" valign="middle">Depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 9.5 μM</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 4.2 μM</td>
              <td align="center" valign="middle">No inhibition at 30 μM</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B103-marinedrugs-10-02181">103</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Tiglicamide A</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 2.14 μM</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B111-marinedrugs-10-02181">111</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Tiglicamide B</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 6.99 μM</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B111-marinedrugs-10-02181">111</xref>]</td>
            </tr>
            <tr>
              <td align="center" valign="middle">Tiglicamide C</td>
              <td align="center" valign="middle">
                <italic>Lyngbya confervoides</italic>
              </td>
              <td align="center" valign="middle">Cyclic depsipeptide</td>
              <td align="center" valign="middle">IC<sub>50</sub> = 7.28 μM</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">Not described</td>
              <td align="center" valign="middle">[<xref ref-type="bibr" rid="B111-marinedrugs-10-02181">111</xref>]</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="marinedrugs-10-02181-f002" position="anchor">
        <label>Figure 2</label>
        <caption>
          <p>Chemical structures of the marine cyanobacterial secondary metabolites symplocamide and kempopeptins A and B.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="marinedrugs-10-02181-g002.tif"/>
      </fig>
      <p>Pitipeptolides A and B, two cyclodepsipeptides isolated from the marine cyanobacteria <italic>Lyngbya majuscula </italic>collected at Guam, revealed a particular bioactivity. When in contact to elastase, these compounds induce a significant increase in activity: 2.76-fold and 2.55-fold, respectively, at 50 μg/mL [<xref ref-type="bibr" rid="B77-marinedrugs-10-02181">77</xref>]. The authors suggested that this biological activity can be attributed to the presence of hydrophobic portions in the molecule [<xref ref-type="bibr" rid="B77-marinedrugs-10-02181">77</xref>].</p>
      <p>Cathepsin D is a lysosomal protease that was described to have both anti-apoptotic [<xref ref-type="bibr" rid="B131-marinedrugs-10-02181">131</xref>] and pro-apoptotic functions [<xref ref-type="bibr" rid="B132-marinedrugs-10-02181">132</xref>]. Cathepsin E, besides its function being not well studied, it was described as a cathepsin D-like protein [<xref ref-type="bibr" rid="B133-marinedrugs-10-02181">133</xref>]. Grassystatins A and B, two linear depsipeptides isolated from <italic>Lyngbya confervoides</italic> were found to strongly inhibit cathepsins D (IC<sub>50</sub> = 26.5 nM and 7.27 nM, respectively) and E (IC<sub>50</sub> = 886 pM and 354 pM) [<xref ref-type="bibr" rid="B95-marinedrugs-10-02181">95</xref>].</p>
    </sec>
    <sec>
      <title>6. Alterations in the Bcl-2 Protein Family</title>
      <p>The Bcl-2 protein family is one of the major apoptosis regulators, which functions in the modulation of the outer mitochondrial membrane. The antiapoptotic members Bcl-2 and Bcl-x<sub>L</sub> protect the membrane integrity and avoid the release of the cytochrome <italic>c</italic>, but their activity can be disturbed by the pro-apoptotic members Bax, Bad and Bid [<xref ref-type="bibr" rid="B28-marinedrugs-10-02181">28</xref>].</p>
      <p>Symplostatin 1 initiates the phosphorylation of Bcl-2, inhibiting its anti-apoptotic properties in human breast cancer cells and the total content of the protein appear also to be decreased [<xref ref-type="bibr" rid="B25-marinedrugs-10-02181">25</xref>]. Exposure to cryptophycin 52 was responsible for Bcl-2 and Bcl-x<sub>L</sub> phosphorylation in several prostate cancer cell lines [<xref ref-type="bibr" rid="B113-marinedrugs-10-02181">113</xref>]. Dolastatin 10 was associated to a Bcl-2 protein content reduction [<xref ref-type="bibr" rid="B56-marinedrugs-10-02181">56</xref>] and suggested to induce phosphorylation of the protein [<xref ref-type="bibr" rid="B53-marinedrugs-10-02181">53</xref>]. These are the common defensive mechanisms, the anti-apoptotic members are downregulated by phosphorylation, to allow the mechanisms of cell survival. However, cells can develop different ways of protection and, surprisingly, the synthetic analogue of dolastatin 10, dolastatin 15, promotes the overexpression of Bcl-2 protein in four different lung cancer cell lines [<xref ref-type="bibr" rid="B134-marinedrugs-10-02181">134</xref>].</p>
      <p>Catassi and co-workers studied the response of non-small cell lung cancer cells when treated with curacin and dolastatins 10 and 15 and observed that these compounds inhibit Bad phosphorylation at serine<sup>136</sup> [<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]. The authors propose that the complex allow Bad to move into the mitochondria and promotes cytochrome <italic>c</italic> release, to trigger apoptosis [<xref ref-type="bibr" rid="B52-marinedrugs-10-02181">52</xref>]. Apart from the cell mechanism developed, the Bcl-2 protein family seems to play a crucial role in apoptosis induced by marine cyanobacterial natural compounds.</p>
    </sec>
    <sec>
      <title>7. Alterations in Membrane Sodium Channel Dynamics</title>
      <p>In mammal cells, a concentration gradient is necessary to keep the high levels of intracellular potassium and the low levels of sodium. This gradient is held by several ionic transporters and channels and by the capacity of cells to adapt to non-isotonic conditions, by volume regulatory mechanisms [<xref ref-type="bibr" rid="B135-marinedrugs-10-02181">135</xref>]. In apoptosis, a disordered volume regulation that leads to cell shrinkage during regular osmotic conditions occurs [<xref ref-type="bibr" rid="B136-marinedrugs-10-02181">136</xref>] leading to an early increase in the intracellular sodium concentration [<xref ref-type="bibr" rid="B137-marinedrugs-10-02181">137</xref>].</p>
      <p>Marine cyanobacterial natural compounds seem to be involved in both induction and inhibition of sodium channels in neural cells. Antillatoxin, a lipopeptide isolated from <italic>Lyngbya majuscule</italic> was responsible for a rapid increase in sodium concentration inside of the cell in primary rat cerebellar granule cells [<xref ref-type="bibr" rid="B86-marinedrugs-10-02181">86</xref>]. Although the mechanism of interaction is not well described, the authors excluded an interaction of antillatoxin with channel neurotoxin sites 1–3, 5 and 7. Hoiamides are a class of cyclic depsipeptides with sodium channel bioactivity [<xref ref-type="bibr" rid="B59-marinedrugs-10-02181">59</xref>,<xref ref-type="bibr" rid="B97-marinedrugs-10-02181">97</xref>]. Hoiamides A and B were described to activate sodium channels in primary cultures of neocortical neurons from embryonic mice, with an IC<sub>50</sub> of 1.7 μM and 3.9 μM, respectively [<xref ref-type="bibr" rid="B59-marinedrugs-10-02181">59</xref>]. In another work it was suggested that hoiamide A acts as a partial agonist at neurotoxin site 2 [<xref ref-type="bibr" rid="B97-marinedrugs-10-02181">97</xref>].</p>
      <p>Palmyramide A, a cyclic depsipeptide from <italic>Lyngbya majuscule</italic>, showed to inhibit a veratridine and ouabain induced sodium overload with an IC<sub>50</sub> value of 17.2 μM. The authors suggested that the inhibition may occur by blocking the voltage-gated sodium channel [<xref ref-type="bibr" rid="B76-marinedrugs-10-02181">76</xref>]. Palmyrolide, a macrolide isolated from an assemblage of <italic>Leptolyngbya </italic>cf. and <italic>Oscillatoria </italic>spp<italic>.</italic>, is a stronger inhibitor of veratridine and ouabain induced sodium overload with an IC<sub>50</sub> value of 3.70 μM [<xref ref-type="bibr" rid="B107-marinedrugs-10-02181">107</xref>].</p>
      <p>Hermitamides A and B are two lipopeptides, isolated from the marine cyanobacteria <italic>Lyngbya majuscula </italic>from a Papua New Guinea collection. Hermitamide A is a sodium channel blocker that inhibits it near to 50% at 1 μM. Hermitamide B is a more potent blocker, inhibiting near to 80% at 1 μM [<xref ref-type="bibr" rid="B96-marinedrugs-10-02181">96</xref>]. It was proposed that the aromatic region of these compounds is important for the channel inhibition, being the indole group of hermitamide B an advantage over the phenyl ring of hermitamide A. A bioinformatic approach reveals that the connection between hermitamide B and human voltage-gated sodium channel is driven mainly by a hydrophobic interaction with residue K1237, and H-bonds between the amide group of hermitamide B with N434 and Y1586. Hydrophobic interactions between hermitamide B and F1283, F1579, L1582, V1583, Y1586, L1280, L788, F791, L792, I433, and L437 residues are also predicted [<xref ref-type="bibr" rid="B96-marinedrugs-10-02181">96</xref>]. </p>
      <p>Alterations in intracellular sodium levels and the interaction between cyanobacterial natural products and the sodium channels are important keys to understand the toxic mechanism and to develop possible pharmacological applications. </p>
    </sec>
    <sec sec-type="conclusions">
      <title>8. Conclusions</title>
      <p>Marine cyanobacteria have been identified as one of the most promising groups of organisms from which novel biochemically active natural products, with potential benefits against cancer, can be isolated. Although several compounds were found to inhibit cell growth in a large variety of cancer cell lines, the pathways by which cancer cells are inhibited are still poorly elucidated. In some cases, compounds were found to induce cell death by activation of the apoptotic process; nevertheless the mechanisms underlying the apoptosis still need more investigations. Some compounds were found to create an imbalance in cellular redox potential, with mitochondria representing a central role in the process. However, more studies are needed in order to clarify if mitochondria and oxidative stress are the direct targets, or if they are just a consequence of upstream damage. Cell cycle is another disturbed process, mainly due to disruption of the microtubules and actin filaments; however there are only a few studies connecting marine cyanobacterial compounds with alterations in cell cycle and more studies are needed in order to clarify the involvement of these compounds in the process. Not surprisingly, the proteins directly involved in apoptosis, caspases, non-caspases proteases and the Bcl-2 protein family, also seem to be associated with the cyanobacterial compounds activity. Even membrane sodium channels can establish interactions with the compounds, revealing its potentially important role in the observed effects.</p>
      <p>In summary, marine cyanobacteria seems to be clearly an important source of anticancer drugs. However, more investigations are needed in order to clarify the specific targets and the mechanisms that are behind cancer cell cytotoxicity, namely the involvement of the apoptotic process. </p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors acknowledge the Portuguese Foundation for Science and Technology (FCT) for financial support with the projects PTDC/MAR/102638/2008, PTDC/MAR/099642/2008, PTDC/MAR/102258/2008 and PesT-C/MAR/LA0015/2011. Margarida Costa has been supported with the FCT grant BTI/PTDC/MAR/102638/2008/2010-025.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1-marinedrugs-10-02181">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsygankov</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Nitrogen-Fixing cyanobacteria: Producents of hydrogen</article-title>
          <source>Prikl. Biokhim. Mikrobiol.</source>
          <year>2007</year>
          <volume>43</volume>
          <fpage>279</fpage>
          <lpage>288</lpage>
        <pub-id pub-id-type="pmid">17619574</pub-id></citation>
      </ref>
      <ref id="B2-marinedrugs-10-02181">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carmichael</surname>
              <given-names>W.W.</given-names>
            </name>
          </person-group>
          <article-title>Cyanobacteria secondary metabolites—the cyanotoxins</article-title>
          <source>J. Appl. Bacteriol.</source>
          <year>1992</year>
          <volume>72</volume>
          <fpage>445</fpage>
          <lpage>459</lpage>
        <pub-id pub-id-type="doi">10.1111/j.1365-2672.1992.tb01858.x</pub-id><pub-id pub-id-type="pmid">1644701</pub-id></citation>
      </ref>
      <ref id="B3-marinedrugs-10-02181">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Codd</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>L.F.</given-names>
            </name>
            <name>
              <surname>Metcalf</surname>
              <given-names>J.S.</given-names>
            </name>
          </person-group>
          <article-title>Cyanobacterial toxins: Risk management for health protection</article-title>
          <source>Toxicol. Appl. Pharmacol.</source>
          <year>2005</year>
          <volume>203</volume>
          <fpage>264</fpage>
          <lpage>272</lpage>
        <pub-id pub-id-type="doi">10.1016/j.taap.2004.02.016</pub-id><pub-id pub-id-type="pmid">15737680</pub-id></citation>
      </ref>
      <ref id="B4-marinedrugs-10-02181">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blaha</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Babica</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Marsalek</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Toxins produced in cyanobacterial water blooms—toxicity and risks</article-title>
          <source>Interdiscip. Toxicol.</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>36</fpage>
          <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.2478/v10102-009-0006-2</pub-id><pub-id pub-id-type="pmid">21217843</pub-id></citation>
      </ref>
      <ref id="B5-marinedrugs-10-02181">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Tiwari</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Rai</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Mohapatra</surname>
              <given-names>T.M.</given-names>
            </name>
          </person-group>
          <article-title>Cyanobacteria: An emerging source for drug discovery</article-title>
          <source>J. Antibiot. (Tokyo)</source>
          <year>2011</year>
          <volume>64</volume>
          <fpage>401</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="doi">10.1038/ja.2011.21</pub-id>
        </citation>
      </ref>
      <ref id="B6-marinedrugs-10-02181">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nunnery</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Mevers</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Biologically active secondary metabolites from marine cyanobacteria</article-title>
          <source>Curr. Opin. Biotechnol.</source>
          <year>2010</year>
          <volume>21</volume>
          <fpage>787</fpage>
          <lpage>793</lpage>
        <pub-id pub-id-type="doi">10.1016/j.copbio.2010.09.019</pub-id><pub-id pub-id-type="pmid">21030245</pub-id></citation>
      </ref>
      <ref id="B7-marinedrugs-10-02181">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Monroe</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Eisman</surname>
              <given-names>E.B.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>The unique mechanistic transformations involved in the biosynthesis of modular natural products from marine cyanobacteria</article-title>
          <source>Nat. Prod. Rep.</source>
          <year>2010</year>
          <volume>27</volume>
          <fpage>1048</fpage>
          <lpage>1065</lpage>
        <pub-id pub-id-type="doi">10.1039/c000535e</pub-id><pub-id pub-id-type="pmid">20442916</pub-id></citation>
      </ref>
      <ref id="B8-marinedrugs-10-02181">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmons</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Ortega-Barria</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium</article-title>
          <source>Tetrahedron Lett.</source>
          <year>2006</year>
          <volume>47</volume>
          <fpage>3387</fpage>
          <lpage>3390</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tetlet.2006.03.082</pub-id></citation>
      </ref>
      <ref id="B9-marinedrugs-10-02181">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sisay</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Hautmann</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mehner</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Konig</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Bajorath</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gutschow</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of human leukocyte elastase by brunsvicamides A–C: Cyanobacterial cyclic peptides</article-title>
          <source>ChemMedChem</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>1425</fpage>
          <lpage>1429</lpage>
          <pub-id pub-id-type="doi">10.1002/cmdc.200900139</pub-id>
        </citation>
      </ref>
      <ref id="B10-marinedrugs-10-02181">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nogle</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Okino</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Antillatoxin B, a neurotoxic lipopeptide from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2001</year>
          <volume>64</volume>
          <fpage>983</fpage>
          <lpage>985</lpage>
          <pub-id pub-id-type="doi">10.1021/np010107f</pub-id>
        </citation>
      </ref>
      <ref id="B11-marinedrugs-10-02181">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>The wewakpeptins, cyclic depsipeptides from a Papua New Guinea collection of the marine cyanobacterium <italic>Lyngbya semiplena</italic></article-title>
          <source>J. Org. Chem.</source>
          <year>2005</year>
          <volume>70</volume>
          <fpage>3133</fpage>
          <lpage>3139</lpage>
          <pub-id pub-id-type="doi">10.1021/jo0478858</pub-id>
        </citation>
      </ref>
      <ref id="B12-marinedrugs-10-02181">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soria-Mercado</surname>
              <given-names>I.E.</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Alotamide A, a novel neuropharmacological agent from the marine cyanobacterium <italic>Lyngbya bouillonii</italic></article-title>
          <source>Org. Lett.</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>4704</fpage>
          <lpage>4707</lpage>
          <pub-id pub-id-type="doi">10.1021/ol901438b</pub-id>
        </citation>
      </ref>
      <ref id="B13-marinedrugs-10-02181">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>T.T.</given-names>
            </name>
            <name>
              <surname>More</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>I.H.</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Jen</surname>
              <given-names>Y.C.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>C.K.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W.S.</given-names>
            </name>
          </person-group>
          <article-title>Isomalyngamide A, A-1 and their analogs suppress cancer cell migration <italic>in vitro</italic></article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2011</year>
          <volume>46</volume>
          <fpage>3810</fpage>
          <lpage>3819</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2011.05.049</pub-id>
        </citation>
      </ref>
      <ref id="B14-marinedrugs-10-02181">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrianasolo</surname>
              <given-names>E.H.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Musafija-Girt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Leal</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Isolation of swinholide A and related glycosylated derivatives from two field collections of marine cyanobacteria</article-title>
          <source>Org. Lett.</source>
          <year>2005</year>
          <volume>7</volume>
          <fpage>1375</fpage>
          <lpage>1378</lpage>
        <pub-id pub-id-type="doi">10.1021/ol050188x</pub-id><pub-id pub-id-type="pmid">15787510</pub-id></citation>
      </ref>
      <ref id="B15-marinedrugs-10-02181">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teruya</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nakayama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Suenaga</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Biselyngbyaside, a macrolide glycoside from the marine cyanobacterium <italic>Lyngbya</italic> sp</article-title>
          <source>Org. Lett.</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>2421</fpage>
          <lpage>2424</lpage>
          <pub-id pub-id-type="doi">10.1021/ol900579k</pub-id>
        </citation>
      </ref>
      <ref id="B16-marinedrugs-10-02181">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salvador</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Caylobolide B, a macrolactone from symplostatin 1-producing marine cyanobacteria <italic>Phormidium</italic> spp. from Florida</article-title>
          <source> J. Nat. Prod.</source>
          <year>2010</year>
          <volume>73</volume>
          <fpage>1606</fpage>
          <lpage>1609</lpage>
          <pub-id pub-id-type="doi">10.1021/np100467d</pub-id>
        </citation>
      </ref>
      <ref id="B17-marinedrugs-10-02181">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montaser</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Pitipeptolides C–F, antimycobacterial cyclodepsipeptides from the marine cyanobacterium <italic>Lyngbya majuscula</italic> from Guam</article-title>
          <source>Phytochemistry</source>
          <year>2011</year>
          <volume>72</volume>
          <fpage>2068</fpage>
          <lpage>2074</lpage>
          <pub-id pub-id-type="doi">10.1016/j.phytochem.2011.07.014</pub-id>
        </citation>
      </ref>
      <ref id="B18-marinedrugs-10-02181">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marquez</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Yokochi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Verdier-Pinard</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Hamel</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Scheuer</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly</article-title>
          <source>J. Nat. Prod.</source>
          <year>2002</year>
          <volume>65</volume>
          <fpage>866</fpage>
          <lpage>871</lpage>
          <pub-id pub-id-type="doi">10.1021/np0106283</pub-id>
        </citation>
      </ref>
      <ref id="B19-marinedrugs-10-02181">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milligan</surname>
              <given-names>K.E.</given-names>
            </name>
            <name>
              <surname>Marquez</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>R.T.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Lyngbyabellin B, a toxic and antifungal secondary metabolite from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2000</year>
          <volume>63</volume>
          <fpage>1440</fpage>
          <lpage>1443</lpage>
          <pub-id pub-id-type="doi">10.1021/np000133y</pub-id>
        </citation>
      </ref>
      <ref id="B20-marinedrugs-10-02181">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tripathi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Puddick</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Prinsep</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Rottmann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>L.T.</given-names>
            </name>
          </person-group>
          <article-title>Lagunamides A and B: Cytotoxic and antimalarial cyclodepsipeptides from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2010</year>
          <volume>73</volume>
          <fpage>1810</fpage>
          <lpage>1814</lpage>
          <pub-id pub-id-type="doi">10.1021/np100442x</pub-id>
        </citation>
      </ref>
      <ref id="B21-marinedrugs-10-02181">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Capper</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cruz-Rivera</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Tibbetts</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Chemical deterrence of a marine cyanobacterium against sympatric and non-sympatric consumers</article-title>
          <source>Hydrobiologia</source>
          <year>2006</year>
          <volume>553</volume>
          <fpage>319</fpage>
          <lpage>326</lpage>
        <pub-id pub-id-type="doi">10.1007/s10750-005-1129-x</pub-id></citation>
      </ref>
      <ref id="B22-marinedrugs-10-02181">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>B.P.</given-names>
            </name>
          </person-group>
          <article-title>Chemical ecology of marine cyanobacterial secondary metabolites: A mini-review</article-title>
          <source>J. Coast. Dev.</source>
          <year>2009</year>
          <volume>13</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </citation>
      </ref>
      <ref id="B23-marinedrugs-10-02181">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malloy</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Matainaho</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Malyngamide 2, an oxidized lipopeptide with nitric oxide inhibiting activity from a Papua New Guinea marine cyanobacterium</article-title>
          <source>J. Nat. Prod.</source>
          <year>2011</year>
          <volume>74</volume>
          <fpage>95</fpage>
          <lpage>98</lpage>
        <pub-id pub-id-type="doi">10.1021/np1005407</pub-id><pub-id pub-id-type="pmid">21155594</pub-id></citation>
      </ref>
      <ref id="B24-marinedrugs-10-02181">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Aurilides B and C, cancer cell toxins from a Papua New Guinea collection of the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2006</year>
          <volume>69</volume>
          <fpage>572</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="doi">10.1021/np0503911</pub-id>
        </citation>
      </ref>
      <ref id="B25-marinedrugs-10-02181">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Leal</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Tinley</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Corbett</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>The molecular pharmacology of symplostatin 1: A new antimitotic dolastatin 10 analog</article-title>
          <source>Int. J. Cancer</source>
          <year>2003</year>
          <volume>104</volume>
          <fpage>512</fpage>
          <lpage>521</lpage>
        <pub-id pub-id-type="doi">10.1002/ijc.10982</pub-id><pub-id pub-id-type="pmid">12584751</pub-id></citation>
      </ref>
      <ref id="B26-marinedrugs-10-02181">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gutierrez</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Suyama</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Wingerd</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Matainaho</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the marine cyanobacteria <italic>Lyngbya majuscula</italic> and <italic>Lyngbya sordida</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2008</year>
          <volume>71</volume>
          <fpage>1099</fpage>
          <lpage>1103</lpage>
          <pub-id pub-id-type="doi">10.1021/np800121a</pub-id>
        </citation>
      </ref>
      <ref id="B27-marinedrugs-10-02181">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linington</surname>
              <given-names>R.G.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Shuman</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Matainaho</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Symplocamide A, a potent cytotoxin and chymotrypsin inhibitor from the marine cyanobacterium <italic>Symploca</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2008</year>
          <volume>71</volume>
          <fpage>22</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="doi">10.1021/np070280x</pub-id>
        </citation>
      </ref>
      <ref id="B28-marinedrugs-10-02181">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ulukaya</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Acilan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yilmaz</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis: Why and how does it occur in biology?</article-title>
          <source>Cell Biochem. Funct.</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>468</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="doi">10.1002/cbf.1774</pub-id>
        </citation>
      </ref>
      <ref id="B29-marinedrugs-10-02181">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Y.S.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Role of apoptotic and necrotic cell death under physiologic conditions</article-title>
          <source>BMB Rep.</source>
          <year>2008</year>
          <volume>41</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
        <pub-id pub-id-type="doi">10.5483/BMBRep.2008.41.1.001</pub-id><pub-id pub-id-type="pmid">18304444</pub-id></citation>
      </ref>
      <ref id="B30-marinedrugs-10-02181">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Suh</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Seoung</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>Y.S.</given-names>
            </name>
          </person-group>
          <article-title>Autophagy as a target for anticancer therapy and its modulation by phytochemicals</article-title>
          <source>J. Food Drug Anal.</source>
          <year>2012</year>
          <volume>20</volume>
          <fpage>241</fpage>
          <lpage>245</lpage>
        </citation>
      </ref>
      <ref id="B31-marinedrugs-10-02181">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis-Based anticancer drugs</article-title>
          <source>Nat. Rev. Drug Discov.</source>
          <year>2002</year>
          <volume>1</volume>
          <fpage>101</fpage>
          <lpage>102</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd742</pub-id><pub-id pub-id-type="pmid">12120090</pub-id></citation>
      </ref>
      <ref id="B32-marinedrugs-10-02181">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Schulze-Osthoff</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis-Based therapies and drug targets</article-title>
          <source>Cell Death Differ.</source>
          <year>2005</year>
          <volume>12</volume>
          <fpage>942</fpage>
          <lpage>961</lpage>
        <pub-id pub-id-type="doi">10.1038/sj.cdd.4401556</pub-id><pub-id pub-id-type="pmid">15665817</pub-id></citation>
      </ref>
      <ref id="B33-marinedrugs-10-02181">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>K.G.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Landis-Piwowar</surname>
              <given-names>K.R.</given-names>
            </name>
            <name>
              <surname>Dou</surname>
              <given-names>Q.P.</given-names>
            </name>
          </person-group>
          <article-title>Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells</article-title>
          <source>Biochem. Pharmacol.</source>
          <year>2005</year>
          <volume>69</volume>
          <fpage>1421</fpage>
          <lpage>1432</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bcp.2005.02.022</pub-id><pub-id pub-id-type="pmid">15857606</pub-id></citation>
      </ref>
      <ref id="B34-marinedrugs-10-02181">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>Y.B.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>Q.F.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>M.X.</given-names>
            </name>
            <name>
              <surname>Ouyang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bao</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>Hydrogen peroxide-induced apoptosis in human gastric carcinoma MGC803 cells</article-title>
          <source>Cell Biol. Int.</source>
          <year>2006</year>
          <volume>30</volume>
          <fpage>332</fpage>
          <lpage>337</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cellbi.2005.12.008</pub-id><pub-id pub-id-type="pmid">16533611</pub-id></citation>
      </ref>
      <ref id="B35-marinedrugs-10-02181">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lytvyn</surname>
              <given-names>D.I.</given-names>
            </name>
            <name>
              <surname>Yemets</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Blume</surname>
              <given-names>Y.B.</given-names>
            </name>
          </person-group>
          <article-title>UV-B overexposure induces programmed cell death in a BY-2 tobacco cell line</article-title>
          <source>Environ. Exp. Bot.</source>
          <year>2010</year>
          <volume>68</volume>
          <fpage>51</fpage>
          <lpage>57</lpage>
        <pub-id pub-id-type="doi">10.1016/j.envexpbot.2009.11.004</pub-id></citation>
      </ref>
      <ref id="B36-marinedrugs-10-02181">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elmore</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis: A review of programmed cell death</article-title>
          <source>Toxicol. Pathol.</source>
          <year>2007</year>
          <volume>35</volume>
          <fpage>495</fpage>
          <lpage>516</lpage>
        <pub-id pub-id-type="doi">10.1080/01926230701320337</pub-id><pub-id pub-id-type="pmid">17562483</pub-id></citation>
      </ref>
      <ref id="B37-marinedrugs-10-02181">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martins</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Ramos</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Herfindal</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sousa</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Skaerven</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Vasconcelos</surname>
              <given-names>V.M.</given-names>
            </name>
          </person-group>
          <article-title>Antimicrobial and cytotoxic assessment of marine cyanobacteria—Synechocystis and Synechococcus</article-title>
          <source>Mar. Drugs</source>
          <year>2008</year>
          <volume>6</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
        <pub-id pub-id-type="doi">10.3390/md6010001</pub-id><pub-id pub-id-type="pmid">18648669</pub-id></citation>
      </ref>
      <ref id="B38-marinedrugs-10-02181">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yonezawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Mase</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Teruya</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cha</surname>
              <given-names>B.Y.</given-names>
            </name>
            <name>
              <surname>Yagasaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Suenaga</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Woo</surname>
              <given-names>J.T.</given-names>
            </name>
          </person-group>
          <article-title>Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts</article-title>
          <source>J. Cell Biochem.</source>
          <year>2012</year>
          <volume>113</volume>
          <fpage>440</fpage>
          <lpage>448</lpage>
          <pub-id pub-id-type="doi">10.1002/jcb.23213</pub-id>
        </citation>
      </ref>
      <ref id="B39-marinedrugs-10-02181">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oftedal</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Selheim</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Wahlsten</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sivonen</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Doskeland</surname>
              <given-names>S.O.</given-names>
            </name>
            <name>
              <surname>Herfindal</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Marine benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill leukemia cells, but not cardiomyocytes</article-title>
          <source>Mar. Drugs</source>
          <year>2010</year>
          <volume>8</volume>
          <fpage>2659</fpage>
          <lpage>2672</lpage>
        <pub-id pub-id-type="doi">10.3390/md8102659</pub-id><pub-id pub-id-type="pmid">21116413</pub-id></citation>
      </ref>
      <ref id="B40-marinedrugs-10-02181">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>New apratoxins of marine cyanobacterial origin from Guam and Palau</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2002</year>
          <volume>10</volume>
          <fpage>1973</fpage>
          <lpage>1978</lpage>
        <pub-id pub-id-type="doi">10.1016/S0968-0896(02)00014-7</pub-id><pub-id pub-id-type="pmid">11937357</pub-id></citation>
      </ref>
      <ref id="B41-marinedrugs-10-02181">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Corbett</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>2001</year>
          <volume>123</volume>
          <fpage>5418</fpage>
          <lpage>5423</lpage>
        <pub-id pub-id-type="doi">10.1021/ja010453j</pub-id><pub-id pub-id-type="pmid">11389621</pub-id></citation>
      </ref>
      <ref id="B42-marinedrugs-10-02181">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matthew</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Schupp</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium <italic>Lyngbya bouillonii</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2008</year>
          <volume>71</volume>
          <fpage>1113</fpage>
          <lpage>1116</lpage>
          <pub-id pub-id-type="doi">10.1021/np700717s</pub-id>
        </citation>
      </ref>
      <ref id="B43-marinedrugs-10-02181">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tidgewell</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Byrum</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Media</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Doi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Valeriote</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Evolved diversification of a modular natural product pathway: Apratoxins F and G, two cytotoxic cyclic depsipeptides from a Palmyra collection of <italic>Lyngbya bouillonii</italic></article-title>
          <source>ChemBioChem</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>1458</fpage>
          <lpage>1466</lpage>
          <pub-id pub-id-type="doi">10.1002/cbic.201000070</pub-id>
        </citation>
      </ref>
      <ref id="B44-marinedrugs-10-02181">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teruya</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Fukazawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Suenaga</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Bisebromoamide, a potent cytotoxic peptide from the marine cyanobacterium <italic>Lyngbya</italic> sp.: isolation, stereostructure, and biological activity</article-title>
          <source>Org. Lett.</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>5062</fpage>
          <lpage>5065</lpage>
        <pub-id pub-id-type="doi">10.1021/ol9020546</pub-id><pub-id pub-id-type="pmid">19803465</pub-id></citation>
      </ref>
      <ref id="B45-marinedrugs-10-02181">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>X.X.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Waring</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Human cancer cell (Jurkat) killing by the cyanobacterial metabolite calothrixin A</article-title>
          <source>J. Appl. Phycol.</source>
          <year>2003</year>
          <volume>15</volume>
          <fpage>269</fpage>
          <lpage>277</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1025134106985</pub-id></citation>
      </ref>
      <ref id="B46-marinedrugs-10-02181">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>Q.A.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hecht</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Calothrixins, a new class of human DNA topoisomerase I poisons</article-title>
          <source>J. Nat. Prod.</source>
          <year>2009</year>
          <volume>72</volume>
          <fpage>438</fpage>
          <lpage>442</lpage>
        <pub-id pub-id-type="doi">10.1021/np8007232</pub-id><pub-id pub-id-type="pmid">19203291</pub-id></citation>
      </ref>
      <ref id="B47-marinedrugs-10-02181">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernardo</surname>
              <given-names>P.H.</given-names>
            </name>
            <name>
              <surname>Chai</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Le Guen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Waring</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Structure-Activity delineation of quinones related to the biologically active Calothrixin B</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2007</year>
          <volume>17</volume>
          <fpage>82</fpage>
          <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmcl.2006.09.090</pub-id><pub-id pub-id-type="pmid">17098429</pub-id></citation>
      </ref>
      <ref id="B48-marinedrugs-10-02181">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MacMillan</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Molinski</surname>
              <given-names>T.F.</given-names>
            </name>
          </person-group>
          <article-title>Caylobolide A, a unique 36-membered macrolactone from a Bahamian <italic>Lyngbya majuscula</italic></article-title>
          <source>Org. Lett.</source>
          <year>2002</year>
          <volume>4</volume>
          <fpage>1535</fpage>
          <lpage>1538</lpage>
          <pub-id pub-id-type="doi">10.1021/ol025759p</pub-id>
        </citation>
      </ref>
      <ref id="B49-marinedrugs-10-02181">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Medina</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Hills</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>L.I.</given-names>
            </name>
            <name>
              <surname>Ortega-Barria</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.L.</given-names>
            </name>
          </person-group>
          <article-title>Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium <italic>Leptolyngbya</italic> sp</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>2008</year>
          <volume>130</volume>
          <fpage>6324</fpage>
          <lpage>6325</lpage>
        <pub-id pub-id-type="doi">10.1021/ja801383f</pub-id><pub-id pub-id-type="pmid">18444611</pub-id></citation>
      </ref>
      <ref id="B50-marinedrugs-10-02181">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Busquets</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Tien</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent</article-title>
          <source>Int. J. Cancer</source>
          <year>1997</year>
          <volume>73</volume>
          <fpage>440</fpage>
          <lpage>448</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19971104)73:3&lt;440::AID-IJC20&gt;3.0.CO;2-F</pub-id>
        </citation>
      </ref>
      <ref id="B51-marinedrugs-10-02181">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wagner</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Shih</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jordan</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>D.C.</given-names>
            </name>
          </person-group>
          <article-title><italic>In vitro</italic> pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines</article-title>
          <source>Cancer Chemother. Pharmacol.</source>
          <year>1999</year>
          <volume>43</volume>
          <fpage>115</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1007/s002800050871</pub-id>
        </citation>
      </ref>
      <ref id="B52-marinedrugs-10-02181">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Catassi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cesario</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Arzani</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Menichini</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Alama</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bruzzo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Imperatori</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rotolo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Granone</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <year>2006</year>
          <volume>63</volume>
          <fpage>2377</fpage>
          <lpage>2386</lpage>
          <pub-id pub-id-type="doi">10.1007/s00018-006-6264-7</pub-id>
        </citation>
      </ref>
      <ref id="B53-marinedrugs-10-02181">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalemkerian</surname>
              <given-names>G.P.</given-names>
            </name>
            <name>
              <surname>Ou</surname>
              <given-names>X.L.</given-names>
            </name>
            <name>
              <surname>Adil</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Rosati</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Khoulani</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Madan</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Pettit</surname>
              <given-names>G.R.</given-names>
            </name>
          </person-group>
          <article-title>Activity of dolastatin 10 against small-cell lung cancer in vitro and <italic>in vivo</italic>: Induction of apoptosis and bcl-2 modification</article-title>
          <source>Cancer Chemother. Pharm.</source>
          <year>1999</year>
          <volume>43</volume>
          <fpage>507</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="doi">10.1007/s002800050931</pub-id>
        </citation>
      </ref>
      <ref id="B54-marinedrugs-10-02181">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turner</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Pettit</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kraft</surname>
              <given-names>A.S.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc</article-title>
          <source>Prostate</source>
          <year>1998</year>
          <volume>34</volume>
          <fpage>175</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0045(19980215)34:3&lt;175::AID-PROS4&gt;3.0.CO;2-H</pub-id>
        </citation>
      </ref>
      <ref id="B55-marinedrugs-10-02181">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beckwith</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Urba</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Longo</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15</article-title>
          <source>J. Natl. Cancer Inst.</source>
          <year>1993</year>
          <volume>85</volume>
          <fpage>483</fpage>
          <lpage>488</lpage>
          <pub-id pub-id-type="doi">10.1093/jnci/85.6.483</pub-id>
        </citation>
      </ref>
      <ref id="B56-marinedrugs-10-02181">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wall</surname>
              <given-names>N.R.</given-names>
            </name>
            <name>
              <surname>Mohammad</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Al-Katib</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh</article-title>
          <source>Leuk. Res.</source>
          <year>1999</year>
          <volume>23</volume>
          <fpage>881</fpage>
          <lpage>888</lpage>
          <pub-id pub-id-type="doi">10.1016/S0145-2126(99)00108-3</pub-id>
        </citation>
      </ref>
      <ref id="B57-marinedrugs-10-02181">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jimenez</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Scheuer</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>New lipopeptides from the Caribbean cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2001</year>
          <volume>64</volume>
          <fpage>200</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="doi">10.1021/np000462q</pub-id>
        </citation>
      </ref>
      <ref id="B58-marinedrugs-10-02181">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Esquenazi</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Byrum</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Dorrestein</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Phylogeny-Guided isolation of ethyl tumonoate A from the marine cyanobacterium cf. <italic>Oscillatoria margaritifera</italic></article-title>
          <source> J. Nat. Prod.</source>
          <year>2011</year>
          <volume>74</volume>
          <fpage>1737</fpage>
          <lpage>1743</lpage>
          <pub-id pub-id-type="doi">10.1021/np200236c</pub-id>
        </citation>
      </ref>
      <ref id="B59-marinedrugs-10-02181">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Shuman</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Byrum</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Matainaho</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Mangoni</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>The hoiamides, structurally intriguing neurotoxic lipopeptides from Papua New Guinea marine cyanobacteria</article-title>
          <source>J. Nat. Prod.</source>
          <year>2010</year>
          <volume>73</volume>
          <fpage>1411</fpage>
          <lpage>1421</lpage>
          <pub-id pub-id-type="doi">10.1021/np100468n</pub-id>
        </citation>
      </ref>
      <ref id="B60-marinedrugs-10-02181">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies-Coleman</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Dzeha</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pannell</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Hendricks</surname>
              <given-names>D.T.</given-names>
            </name>
            <name>
              <surname>Arendse</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>Isolation of homodolastatin 16, a new cyclic depsipeptide from a Kenyan collection of <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2003</year>
          <volume>66</volume>
          <fpage>712</fpage>
          <lpage>715</lpage>
          <pub-id pub-id-type="doi">10.1021/np030014t</pub-id>
        </citation>
      </ref>
      <ref id="B61-marinedrugs-10-02181">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Marquez</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Nogle</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Structure and biosynthesis of the jamaicamides, new mixed polyketide-peptide neurotoxins from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>Chem. Biol.</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>817</fpage>
          <lpage>833</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chembiol.2004.03.030</pub-id>
        </citation>
      </ref>
      <ref id="B62-marinedrugs-10-02181">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>White</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Valeriote</surname>
              <given-names>F.A.</given-names>
            </name>
          </person-group>
          <article-title>Total synthesis and biological evaluation of (+)-kalkitoxin, a cytotoxic metabolite of the cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>Org. Biomol. Chem.</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>2092</fpage>
          <lpage>2102</lpage>
          <pub-id pub-id-type="doi">10.1039/b404205k</pub-id>
        </citation>
      </ref>
      <ref id="B63-marinedrugs-10-02181">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tripathi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Puddick</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Prinsep</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Rottmann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D.Y.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>L.T.</given-names>
            </name>
          </person-group>
          <article-title>Lagunamide C, a cytotoxic cyclodepsipeptide from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>Phytochemistry</source>
          <year>2011</year>
          <volume>72</volume>
          <fpage>2369</fpage>
          <lpage>2375</lpage>
          <pub-id pub-id-type="doi">10.1016/j.phytochem.2011.08.019</pub-id>
        </citation>
      </ref>
      <ref id="B64-marinedrugs-10-02181">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taori</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium <italic>Symploca</italic> sp</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>2008</year>
          <volume>130</volume>
          <fpage>1806</fpage>
          <lpage>1807</lpage>
          <pub-id pub-id-type="doi">10.1021/ja7110064</pub-id>
        </citation>
      </ref>
      <ref id="B65-marinedrugs-10-02181">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Nicklaus</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells</article-title>
          <source>Org. Lett.</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>1368</fpage>
          <lpage>1371</lpage>
          <pub-id pub-id-type="doi">10.1021/ol100308a</pub-id>
        </citation>
      </ref>
      <ref id="B66-marinedrugs-10-02181">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>Isolation, structure determination, and biological activity of Lyngbyabellin A from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2000</year>
          <volume>63</volume>
          <fpage>611</fpage>
          <lpage>615</lpage>
          <pub-id pub-id-type="doi">10.1021/np990543q</pub-id>
        </citation>
      </ref>
      <ref id="B67-marinedrugs-10-02181">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Harrigan</surname>
              <given-names>G.G.</given-names>
            </name>
            <name>
              <surname>Doom</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>Lyngbyaloside B, a new glycoside macrolide from a Palauan marine cyanobacterium, <italic>Lyngbya</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2002</year>
          <volume>65</volume>
          <fpage>1945</fpage>
          <lpage>1948</lpage>
          <pub-id pub-id-type="doi">10.1021/np0202879</pub-id>
        </citation>
      </ref>
      <ref id="B68-marinedrugs-10-02181">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pettit</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Hogan</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Nogawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Cichacz</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Pettit</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>Q.H.</given-names>
            </name>
            <name>
              <surname>Cragg</surname>
              <given-names>G.M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms (1a,)</article-title>
          <source>J. Nat. Prod.</source>
          <year>2008</year>
          <volume>71</volume>
          <fpage>438</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="doi">10.1021/np700738k</pub-id>
        </citation>
      </ref>
      <ref id="B69-marinedrugs-10-02181">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horgen</surname>
              <given-names>F.D.</given-names>
            </name>
            <name>
              <surname>Kazmierski</surname>
              <given-names>E.B.</given-names>
            </name>
            <name>
              <surname>Westenburg</surname>
              <given-names>H.E.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Scheuer</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Malevamide D: Isolation and structure determination of an isodolastatin H analogue from the marine cyanobacterium <italic>Symploca hydnoides</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2002</year>
          <volume>65</volume>
          <fpage>487</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="doi">10.1021/np010560r</pub-id>
        </citation>
      </ref>
      <ref id="B70-marinedrugs-10-02181">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gross</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Valeriote</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Two cytotoxic stereoisomers of malyngamide C, 8-epi-malyngamide C and 8-O-acetyl-8-epi-malyngamide C, from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>Phytochemistry</source>
          <year>2010</year>
          <volume>71</volume>
          <fpage>1729</fpage>
          <lpage>1735</lpage>
          <pub-id pub-id-type="doi">10.1016/j.phytochem.2010.07.001</pub-id>
        </citation>
      </ref>
      <ref id="B71-marinedrugs-10-02181">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gutierrez</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tidgewell</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Capson</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Almanza</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schemies</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Malyngolide dimer, a bioactive symmetric cyclodepside from the panamanian marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2010</year>
          <volume>73</volume>
          <fpage>709</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="doi">10.1021/np9005184</pub-id>
        </citation>
      </ref>
      <ref id="B72-marinedrugs-10-02181">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golakoti</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Chaganty</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and structure determination of nostocyclopeptides A1 and A2 from the terrestrial cyanobacterium <italic>Nostoc</italic> sp. ATCC53789</article-title>
          <source> J. Nat. Prod.</source>
          <year>2001</year>
          <volume>64</volume>
          <fpage>54</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.1021/np000316k</pub-id>
        </citation>
      </ref>
      <ref id="B73-marinedrugs-10-02181">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and structure determination of obyanamide, a novel cytotoxic cyclic depsipeptide from the marine cyanobacterium <italic>Lyngbya confervoides</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2002</year>
          <volume>65</volume>
          <fpage>29</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1021/np0102253</pub-id>
        </citation>
      </ref>
      <ref id="B74-marinedrugs-10-02181">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zou</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Total synthesis and cytotoxicity studies of a cyclic depsipeptide with proposed structure of palau’amide</article-title>
          <source>Org. Lett.</source>
          <year>2005</year>
          <volume>7</volume>
          <fpage>4237</fpage>
          <lpage>4240</lpage>
        <pub-id pub-id-type="doi">10.1021/ol051685g</pub-id><pub-id pub-id-type="pmid">16146396</pub-id></citation>
      </ref>
      <ref id="B75-marinedrugs-10-02181">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Quon</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>The structure of Palau’amide, a potent cytotoxin from a species of the marine cyanobacterium <italic>Lyngbya</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2003</year>
          <volume>66</volume>
          <fpage>1545</fpage>
          <lpage>1549</lpage>
          <pub-id pub-id-type="doi">10.1021/np034001r</pub-id>
        </citation>
      </ref>
      <ref id="B76-marinedrugs-10-02181">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taniguchi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nunnery</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Esquenazi</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Byrum</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Dorrestein</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Palmyramide A, a cyclic depsipeptide from a Palmyra Atoll collection of the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2010</year>
          <volume>73</volume>
          <fpage>393</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="doi">10.1021/np900428h</pub-id>
        </citation>
      </ref>
      <ref id="B77-marinedrugs-10-02181">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Pangilinan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>Pitipeptolides A and B, new cyclodepsipeptides from the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2001</year>
          <volume>64</volume>
          <fpage>304</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1021/np000456u</pub-id>
        </citation>
      </ref>
      <ref id="B78-marinedrugs-10-02181">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montaser</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Abboud</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Pitiprolamide, a proline-rich dolastatin 16 analogue from the marine cyanobacterium <italic>Lyngbya majuscula</italic> from Guam</article-title>
          <source>J. Nat. Prod.</source>
          <year>2011</year>
          <volume>74</volume>
          <fpage>109</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="doi">10.1021/np1006839</pub-id>
        </citation>
      </ref>
      <ref id="B79-marinedrugs-10-02181">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wrasidlo</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Mielgo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Torres</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Barbero</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Stoletov</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Suyama</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Klemke</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Carson</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Stupack</surname>
              <given-names>D.G.</given-names>
            </name>
          </person-group>
          <article-title>The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2008</year>
          <volume>105</volume>
          <fpage>2313</fpage>
          <lpage>2318</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0712198105</pub-id><pub-id pub-id-type="pmid">18268346</pub-id></citation>
      </ref>
      <ref id="B80-marinedrugs-10-02181">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harrigan</surname>
              <given-names>G.G.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Nagle</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Corbett</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Valeriote</surname>
              <given-names>F.A.</given-names>
            </name>
          </person-group>
          <article-title>Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium <italic>Symploca hydnoides</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>1998</year>
          <volume>61</volume>
          <fpage>1075</fpage>
          <lpage>1077</lpage>
          <pub-id pub-id-type="doi">10.1021/np980321c</pub-id>
        </citation>
      </ref>
      <ref id="B81-marinedrugs-10-02181">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>Tasiamide, a cytotoxic peptide from the marine cyanobacterium <italic>Symploca</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2002</year>
          <volume>65</volume>
          <fpage>1336</fpage>
          <lpage>1339</lpage>
          <pub-id pub-id-type="doi">10.1021/np020184q</pub-id>
        </citation>
      </ref>
      <ref id="B82-marinedrugs-10-02181">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>The isolation and structure elucidation of Tasiamide B, a 4-amino-3-hydroxy-5-phenylpentanoic acid containing peptide from the marine Cyanobacterium <italic>Symploca</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2003</year>
          <volume>66</volume>
          <fpage>1006</fpage>
          <lpage>1009</lpage>
          <pub-id pub-id-type="doi">10.1021/np030114z</pub-id>
        </citation>
      </ref>
      <ref id="B83-marinedrugs-10-02181">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>Tasipeptins A and B: New cytotoxic depsipeptides from the marine cyanobacterium <italic>Symploca</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2003</year>
          <volume>66</volume>
          <fpage>620</fpage>
          <lpage>624</lpage>
          <pub-id pub-id-type="doi">10.1021/np020582t</pub-id>
        </citation>
      </ref>
      <ref id="B84-marinedrugs-10-02181">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Quon</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>Ulongapeptin, a cytotoxic cyclic depsipeptide from a Palauan marine cyanobacterium <italic>Lyngbya</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2003</year>
          <volume>66</volume>
          <fpage>651</fpage>
          <lpage>654</lpage>
          <pub-id pub-id-type="doi">10.1021/np030050s</pub-id>
        </citation>
      </ref>
      <ref id="B85-marinedrugs-10-02181">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mevers</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W.T.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mohimani</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Byrum</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Pevzner</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Dorrestein</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Spadafora</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Cytotoxic veraguamides, alkynyl bromide-containing cyclic depsipeptides from the marine cyanobacterium cf. <italic>Oscillatoria margaritifera</italic></article-title>
          <source> J. Nat. Prod.</source>
          <year>2011</year>
          <volume>74</volume>
          <fpage>928</fpage>
          <lpage>936</lpage>
          <pub-id pub-id-type="doi">10.1021/np200077f</pub-id>
        </citation>
      </ref>
      <ref id="B86-marinedrugs-10-02181">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>W.I.</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>F.W.</given-names>
            </name>
            <name>
              <surname>Okino</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yokokawa</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Shioiri</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
          </person-group>
          <article-title>Antillatoxin is a marine cyanobacterial toxin that potently activates voltage-gated sodium channels</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>7599</fpage>
          <lpage>7604</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.121085898</pub-id>
        </citation>
      </ref>
      <ref id="B87-marinedrugs-10-02181">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
          </person-group>
          <article-title>Antillatoxin is a sodium channel activator that displays unique efficacy in heterologously expressed rNav1.2, rNav1.4 and rNav1.5 alpha subunits</article-title>
          <source>BMC Neurosci.</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>154</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2202-11-154</pub-id>
        </citation>
      </ref>
      <ref id="B88-marinedrugs-10-02181">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J.O.</given-names>
            </name>
          </person-group>
          <article-title>Total synthesis of the cyclodepsipeptide apratoxin A and its analogues and assessment of their biological activities</article-title>
          <source>Chemistry</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>7615</fpage>
          <lpage>7626</lpage>
          <pub-id pub-id-type="doi">10.1002/chem.200600599</pub-id>
        </citation>
      </ref>
      <ref id="B89-marinedrugs-10-02181">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation</article-title>
          <source>Mol. Pharmacol.</source>
          <year>2009</year>
          <volume>76</volume>
          <fpage>91</fpage>
          <lpage>104</lpage>
          <pub-id pub-id-type="doi">10.1124/mol.109.056085</pub-id>
        </citation>
      </ref>
      <ref id="B90-marinedrugs-10-02181">
        <label>90.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sumiya</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Shimogawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Tsutsumi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yoshita</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ojika</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Suenaga</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Uesugi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Cell-Morphology profiling of a natural product library identifies bisebromoamide and miuraenamide A as actin filament stabilizers</article-title>
          <source>ACS Chem. Biol.</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>425</fpage>
          <lpage>431</lpage>
          <pub-id pub-id-type="doi">10.1021/cb1003459</pub-id>
        </citation>
      </ref>
      <ref id="B91-marinedrugs-10-02181">
        <label>91.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubio</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Parrish</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schupp</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Schils</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>P.G.</given-names>
            </name>
          </person-group>
          <article-title>Depsipeptides from a Guamanian Marine Cyanobacterium, <italic>Lyngbya bouillonii</italic>, with selective inhibition of serine proteases</article-title>
          <source>Tetrahedron Lett.</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>6718</fpage>
          <lpage>6721</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tetlet.2010.10.062</pub-id>
        </citation>
      </ref>
      <ref id="B92-marinedrugs-10-02181">
        <label>92.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Proteau</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Nagle</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Hamel</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Blokhin</surname>
              <given-names>A.V.</given-names>
            </name>
            <name>
              <surname>Slate</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Structure of Curacin A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the Marine Cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>J. Org. Chem.</source>
          <year>1994</year>
          <volume>59</volume>
          <fpage>1243</fpage>
          <lpage>1245</lpage>
          <pub-id pub-id-type="doi">10.1021/jo00085a006</pub-id>
        </citation>
      </ref>
      <ref id="B93-marinedrugs-10-02181">
        <label>93.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mitra</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sept</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin</article-title>
          <source>Biochemistry</source>
          <year>2004</year>
          <volume>43</volume>
          <fpage>13955</fpage>
          <lpage>13962</lpage>
          <pub-id pub-id-type="doi">10.1021/bi0487387</pub-id>
        </citation>
      </ref>
      <ref id="B94-marinedrugs-10-02181">
        <label>94.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harrigan</surname>
              <given-names>G.G.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Nagle</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>P.U.</given-names>
            </name>
            <name>
              <surname>Biggs</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Corbett</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Valeriote</surname>
              <given-names>F.A.</given-names>
            </name>
          </person-group>
          <article-title>Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from <italic>Lyngbya majuscula</italic>/<italic>Schizothrix calcicola</italic> cyanobacterial assemblages</article-title>
          <source>J. Nat. Prod.</source>
          <year>1998</year>
          <volume>61</volume>
          <fpage>1221</fpage>
          <lpage>1225</lpage>
          <pub-id pub-id-type="doi">10.1021/np9801211</pub-id>
        </citation>
      </ref>
      <ref id="B95-marinedrugs-10-02181">
        <label>95.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwan</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Eksioglu</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Grassystatins A–C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation</article-title>
          <source>J. Med. Chem.</source>
          <year>2009</year>
          <volume>52</volume>
          <fpage>5732</fpage>
          <lpage>5747</lpage>
        <pub-id pub-id-type="doi">10.1021/jm9009394</pub-id><pub-id pub-id-type="pmid">19715320</pub-id></citation>
      </ref>
      <ref id="B96-marinedrugs-10-02181">
        <label>96.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Oliveira</surname>
              <given-names>E.O.</given-names>
            </name>
            <name>
              <surname>Graf</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Baheti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>MacArthur</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Dakshanamurthy</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Paige</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and evaluation of hermitamides A and B as human voltage-gated sodium channel blockers</article-title>
          <source>Bioorg. Med. Chem.</source>
          <year>2011</year>
          <volume>19</volume>
          <fpage>4322</fpage>
          <lpage>4329</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bmc.2011.05.043</pub-id><pub-id pub-id-type="pmid">21683602</pub-id></citation>
      </ref>
      <ref id="B97-marinedrugs-10-02181">
        <label>97.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pereira</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Hoiamide a, a sodium channel activator of unusual architecture from a consortium of two papua new Guinea cyanobacteria</article-title>
          <source>Chem. Biol.</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>893</fpage>
          <lpage>906</lpage>
        <pub-id pub-id-type="doi">10.1016/j.chembiol.2009.06.012</pub-id><pub-id pub-id-type="pmid">19716479</pub-id></citation>
      </ref>
      <ref id="B98-marinedrugs-10-02181">
        <label>98.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LePage</surname>
              <given-names>K.T.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Yokokawa</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Asano</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shioiri</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
          </person-group>
          <article-title>The neurotoxic lipopeptide kalkitoxin interacts with voltage-sensitive sodium channels in cerebellar granule neurons</article-title>
          <source>Toxicol. Lett.</source>
          <year>2005</year>
          <volume>158</volume>
          <fpage>133</fpage>
          <lpage>139</lpage>
        <pub-id pub-id-type="doi">10.1016/j.toxlet.2005.03.007</pub-id><pub-id pub-id-type="pmid">16039402</pub-id></citation>
      </ref>
      <ref id="B99-marinedrugs-10-02181">
        <label>99.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taori</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Kempopeptins A and B, serine protease inhibitors with different selectivity profiles from a marine cyanobacterium, <italic>Lyngbya</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2008</year>
          <volume>71</volume>
          <fpage>1625</fpage>
          <lpage>1629</lpage>
          <pub-id pub-id-type="doi">10.1021/np8002172</pub-id>
        </citation>
      </ref>
      <ref id="B100-marinedrugs-10-02181">
        <label>100.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matthew</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Largamides A–C, tiglic acid-containing cyclodepsipeptides with elastase-inhibitory activity from the marine cyanobacterium <italic>Lyngbya confervoides</italic></article-title>
          <source>Planta Med.</source>
          <year>2009</year>
          <volume>75</volume>
          <fpage>528</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0029-1185332</pub-id>
        </citation>
      </ref>
      <ref id="B101-marinedrugs-10-02181">
        <label>101.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Plaza</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bewley</surname>
              <given-names>C.A.</given-names>
            </name>
          </person-group>
          <article-title>Largamides A–H, unusual cyclic peptides from the marine cyanobacterium <italic>Oscillatoria</italic> sp</article-title>
          <source>J. Org. Chem.</source>
          <year>2006</year>
          <volume>71</volume>
          <fpage>6898</fpage>
          <lpage>6907</lpage>
          <pub-id pub-id-type="doi">10.1021/jo061044e</pub-id>
        </citation>
      </ref>
      <ref id="B102-marinedrugs-10-02181">
        <label>102.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matthew</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rocca</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium <italic>Lyngbya confervoides</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2007</year>
          <volume>70</volume>
          <fpage>124</fpage>
          <lpage>127</lpage>
          <pub-id pub-id-type="doi">10.1021/np060471k</pub-id>
        </citation>
      </ref>
      <ref id="B103-marinedrugs-10-02181">
        <label>103.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taori</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Matthew</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rocca</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Lyngbyastatins 5–7, potent elastase inhibitors from Floridian marine cyanobacteria, <italic>Lyngbya</italic> sp</article-title>
          <source>J. Nat. Prod.</source>
          <year>2007</year>
          <volume>70</volume>
          <fpage>1593</fpage>
          <lpage>1600</lpage>
          <pub-id pub-id-type="doi">10.1021/np0702436</pub-id>
        </citation>
      </ref>
      <ref id="B104-marinedrugs-10-02181">
        <label>104.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwan</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Taori</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Lyngbyastatins 8–10, elastase inhibitors with cyclic depsipeptide scaffolds isolated from the marine cyanobacterium <italic>Lyngbya semiplena</italic></article-title>
          <source>Mar. Drugs</source>
          <year>2009</year>
          <volume>7</volume>
          <fpage>528</fpage>
          <lpage>538</lpage>
          <pub-id pub-id-type="doi">10.3390/md7040528</pub-id>
        </citation>
      </ref>
      <ref id="B105-marinedrugs-10-02181">
        <label>105.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Porzgen</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pittman</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Westenburg</surname>
              <given-names>H.E.</given-names>
            </name>
            <name>
              <surname>Horgen</surname>
              <given-names>F.D.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and structure determination of malevamide E, a dolastatin 14 analogue, from the marine cyanobacterium <italic>Symploca laete-viridis</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2008</year>
          <volume>71</volume>
          <fpage>750</fpage>
          <lpage>754</lpage>
          <pub-id pub-id-type="doi">10.1021/np070346o</pub-id>
        </citation>
      </ref>
      <ref id="B106-marinedrugs-10-02181">
        <label>106.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gunasekera</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Kwan</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
          </person-group>
          <article-title>Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium <italic>Dichothrix utahensis</italic></article-title>
          <source>J. Nat. Prod.</source>
          <year>2010</year>
          <volume>73</volume>
          <fpage>459</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="doi">10.1021/np900603f</pub-id>
        </citation>
      </ref>
      <ref id="B107-marinedrugs-10-02181">
        <label>107.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pereira</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Engene</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Soria-Mercado</surname>
              <given-names>I.E.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Palmyrolide A, an unusually stabilized neuroactive macrolide from Palmyra Atoll cyanobacteria</article-title>
          <source>Org. Lett.</source>
          <year>2010</year>
          <volume>12</volume>
          <fpage>4490</fpage>
          <lpage>4493</lpage>
        <pub-id pub-id-type="doi">10.1021/ol101752n</pub-id><pub-id pub-id-type="pmid">20845912</pub-id></citation>
      </ref>
      <ref id="B108-marinedrugs-10-02181">
        <label>108.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matthew</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Pompanopeptins A and B, new cyclic peptides from the marine cyanobacterium <italic>Lyngbya confervoides</italic></article-title>
          <source>Tetrahedron</source>
          <year>2008</year>
          <volume>64</volume>
          <fpage>4081</fpage>
          <lpage>4089</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tet.2008.02.035</pub-id>
        </citation>
      </ref>
      <ref id="B109-marinedrugs-10-02181">
        <label>109.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Corbett</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Isolation of dolastatin 10 from the marine cyanobacterium <italic>Symploca</italic> species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1</article-title>
          <source>J. Nat. Prod.</source>
          <year>2001</year>
          <volume>64</volume>
          <fpage>907</fpage>
          <lpage>910</lpage>
          <pub-id pub-id-type="doi">10.1021/np010049y</pub-id>
        </citation>
      </ref>
      <ref id="B110-marinedrugs-10-02181">
        <label>110.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>W.Y.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Corbett</surname>
              <given-names>T.H.</given-names>
            </name>
          </person-group>
          <article-title>Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium <italic>Symploca</italic> sp. VP452</article-title>
          <source> J. Nat. Prod.</source>
          <year>2002</year>
          <volume>65</volume>
          <fpage>16</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="doi">10.1021/np010317s</pub-id>
        </citation>
      </ref>
      <ref id="B111-marinedrugs-10-02181">
        <label>111.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matthew</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>V.J.</given-names>
            </name>
            <name>
              <surname>Luesch</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Tiglicamides A–C, cyclodepsipeptides from the marine cyanobacterium <italic>Lyngbya confervoides</italic></article-title>
          <source>Phytochemistry</source>
          <year>2009</year>
          <volume>70</volume>
          <fpage>2058</fpage>
          <lpage>2063</lpage>
          <pub-id pub-id-type="doi">10.1016/j.phytochem.2009.09.010</pub-id>
        </citation>
      </ref>
      <ref id="B112-marinedrugs-10-02181">
        <label>112.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>L.T.</given-names>
            </name>
          </person-group>
          <article-title>Filamentous tropical marine cyanobacteria: a rich source of natural products for anticancer drug discovery</article-title>
          <source>J. Appl. Phycol.</source>
          <year>2010</year>
          <volume>22</volume>
          <fpage>659</fpage>
          <lpage>676</lpage>
          <pub-id pub-id-type="doi">10.1007/s10811-010-9506-x</pub-id>
        </citation>
      </ref>
      <ref id="B113-marinedrugs-10-02181">
        <label>113.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drew</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Fine</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Do</surname>
              <given-names>T.N.</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>G.P.</given-names>
            </name>
            <name>
              <surname>Petrylak</surname>
              <given-names>D.P.</given-names>
            </name>
          </person-group>
          <article-title>The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells</article-title>
          <source>Clin. Cancer Res.</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>3922</fpage>
          <lpage>3932</lpage>
        <pub-id pub-id-type="pmid">12473608</pub-id></citation>
      </ref>
      <ref id="B114-marinedrugs-10-02181">
        <label>114.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sagawa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nakazato</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kizaki</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells</article-title>
          <source>Int. J. Oncol.</source>
          <year>2007</year>
          <volume>30</volume>
          <fpage>1453</fpage>
          <lpage>1459</lpage>
        <pub-id pub-id-type="pmid">17487366</pub-id></citation>
      </ref>
      <ref id="B115-marinedrugs-10-02181">
        <label>115.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagarajan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Maruthanayagam</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Sundararaman</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A review of pharmacological and toxicological potentials of marine cyanobacterial metabolites</article-title>
          <source>J. Appl. Toxicol.</source>
          <year>2012</year>
          <volume>32</volume>
          <fpage>153</fpage>
          <lpage>155</lpage>
        <pub-id pub-id-type="doi">10.1002/jat.1717</pub-id><pub-id pub-id-type="pmid">21910132</pub-id></citation>
      </ref>
      <ref id="B116-marinedrugs-10-02181">
        <label>116.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>B.N.</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Mooberry</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Gerwick</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and structure of five lyngbyabellin derivatives from a Papua New Guinea collection of the marine cyanobacterium <italic>Lyngbya majuscula</italic></article-title>
          <source>Tetrahedron</source>
          <year>2005</year>
          <volume>61</volume>
          <fpage>11723</fpage>
          <lpage>11729</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tet.2005.09.036</pub-id></citation>
      </ref>
      <ref id="B117-marinedrugs-10-02181">
        <label>117.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paradies</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Petrosillo</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Paradies</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Ruggiero</surname>
              <given-names>F.M.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial dysfunction in brain aging: role of oxidative stress and cardiolipin</article-title>
          <source>Neurochem. Int.</source>
          <year>2011</year>
          <volume>58</volume>
          <fpage>447</fpage>
          <lpage>457</lpage>
        <pub-id pub-id-type="doi">10.1016/j.neuint.2010.12.016</pub-id><pub-id pub-id-type="pmid">21215780</pub-id></citation>
      </ref>
      <ref id="B118-marinedrugs-10-02181">
        <label>118.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mammucari</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rizzuto</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Signaling pathways in mitochondrial dysfunction and aging</article-title>
          <source>Mech. Ageing Dev.</source>
          <year>2010</year>
          <volume>131</volume>
          <fpage>536</fpage>
          <lpage>543</lpage>
        <pub-id pub-id-type="doi">10.1016/j.mad.2010.07.003</pub-id><pub-id pub-id-type="pmid">20655326</pub-id></citation>
      </ref>
      <ref id="B119-marinedrugs-10-02181">
        <label>119.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Orihara</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shirakawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Suenaga</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kigoshi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Uesugi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Marine natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin</article-title>
          <source>Chem. Biol.</source>
          <year>2011</year>
          <volume>18</volume>
          <fpage>131</fpage>
          <lpage>139</lpage>
        <pub-id pub-id-type="doi">10.1016/j.chembiol.2010.10.017</pub-id><pub-id pub-id-type="pmid">21276946</pub-id></citation>
      </ref>
      <ref id="B120-marinedrugs-10-02181">
        <label>120.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valko</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Leibfritz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Moncol</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cronin</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Mazur</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Telser</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Free radicals and antioxidants in normal physiological functions and human disease</article-title>
          <source>Int. J. Biochem. Cell Biol.</source>
          <year>2007</year>
          <volume>39</volume>
          <fpage>44</fpage>
          <lpage>84</lpage>
        <pub-id pub-id-type="doi">10.1016/j.biocel.2006.07.001</pub-id><pub-id pub-id-type="pmid">16978905</pub-id></citation>
      </ref>
      <ref id="B121-marinedrugs-10-02181">
        <label>121.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blokhina</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Virolainen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Fagerstedt</surname>
              <given-names>K.V.</given-names>
            </name>
          </person-group>
          <article-title>Antioxidants, oxidative damage and oxygen deprivation stress: A review</article-title>
          <source>Ann. Bot.</source>
          <year>2003</year>
          <volume>91</volume>
          <fpage>179</fpage>
          <lpage>194</lpage>
        <pub-id pub-id-type="doi">10.1093/aob/mcf118</pub-id><pub-id pub-id-type="pmid">12509339</pub-id></citation>
      </ref>
      <ref id="B122-marinedrugs-10-02181">
        <label>122.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Ben-Amotz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Berman-Frank</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Carotenoids provide the major antioxidant defence in the globally significant N2-fixing marine cyanobacterium <italic>Trichodesmium</italic></article-title>
          <source>Environ. Microbiol.</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>1897</fpage>
          <lpage>1908</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1462-2920.2009.01913.x</pub-id>
        </citation>
      </ref>
      <ref id="B123-marinedrugs-10-02181">
        <label>123.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mishra</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>P.K.</given-names>
            </name>
          </person-group>
          <article-title>Antioxidant potential of C-phycocyanin isolated from cyanobacterial species <italic>Lyngbya</italic>, <italic>Phormidium</italic> and <italic>Spirulina</italic> spp</article-title>
          <source>Indian J. Biochem. Biophys.</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>25</fpage>
          <lpage>31</lpage>
        <pub-id pub-id-type="pmid">16955748</pub-id></citation>
      </ref>
      <ref id="B124-marinedrugs-10-02181">
        <label>124.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donepudi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Grutter</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Structure and zymogen activation of caspases</article-title>
          <source>Biophys. Chem.</source>
          <year>2002</year>
          <volume>101</volume>
          <fpage>145</fpage>
          <lpage>153</lpage>
        <pub-id pub-id-type="doi">10.1016/S0301-4622(02)00151-5</pub-id><pub-id pub-id-type="pmid">12487996</pub-id></citation>
      </ref>
      <ref id="B125-marinedrugs-10-02181">
        <label>125.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuentes-Prior</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Salvesen</surname>
              <given-names>G.S.</given-names>
            </name>
          </person-group>
          <article-title>The protein structures that shape caspase activity, specificity, activation and inhibition</article-title>
          <source>Biochem. J.</source>
          <year>2004</year>
          <volume>384</volume>
          <fpage>201</fpage>
          <lpage>232</lpage>
          <pub-id pub-id-type="doi">10.1042/BJ20041142</pub-id>
        </citation>
      </ref>
      <ref id="B126-marinedrugs-10-02181">
        <label>126.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilkinson</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Cepero</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Boise</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Duckett</surname>
              <given-names>C.S.</given-names>
            </name>
          </person-group>
          <article-title>Upstream regulatory role for XIAP in receptor-mediated apoptosis</article-title>
          <source>Mol. Cell. Biol.</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>7003</fpage>
          <lpage>7014</lpage>
        <pub-id pub-id-type="doi">10.1128/MCB.24.16.7003-7014.2004</pub-id><pub-id pub-id-type="pmid">15282301</pub-id></citation>
      </ref>
      <ref id="B127-marinedrugs-10-02181">
        <label>127.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okuno</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nomura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Tsujimoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Bcl-2 prevents caspase-independent cell death</article-title>
          <source>J. Biol. Chem.</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>34272</fpage>
          <lpage>34277</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.273.51.34272</pub-id><pub-id pub-id-type="pmid">9852091</pub-id></citation>
      </ref>
      <ref id="B128-marinedrugs-10-02181">
        <label>128.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schrader</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Huai</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Jockel</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Oberle</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Borner</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Non-Caspase proteases: Triggers or amplifiers of apoptosis?</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <year>2010</year>
          <volume>67</volume>
          <fpage>1607</fpage>
          <lpage>1618</lpage>
          <pub-id pub-id-type="doi">10.1007/s00018-010-0287-9</pub-id>
        </citation>
      </ref>
      <ref id="B129-marinedrugs-10-02181">
        <label>129.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turk</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Targeting proteases: Successes, failures and future prospects</article-title>
          <source>Nat. Rev. Drug Discov.</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>785</fpage>
          <lpage>799</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd2092</pub-id><pub-id pub-id-type="pmid">16955069</pub-id></citation>
      </ref>
      <ref id="B130-marinedrugs-10-02181">
        <label>130.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Henkart</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Apoptotic cell death induced by intracellular proteolysis</article-title>
          <source>J. Immunol.</source>
          <year>1994</year>
          <volume>153</volume>
          <fpage>4247</fpage>
          <lpage>4255</lpage>
        <pub-id pub-id-type="pmid">7930626</pub-id></citation>
      </ref>
      <ref id="B131-marinedrugs-10-02181">
        <label>131.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sagulenko</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Muth</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sagulenko</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Paffhausen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Schwab</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Westermann</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death</article-title>
          <source>Carcinogenesis</source>
          <year>2008</year>
          <volume>29</volume>
          <fpage>1869</fpage>
          <lpage>1877</lpage>
        <pub-id pub-id-type="doi">10.1093/carcin/bgn147</pub-id><pub-id pub-id-type="pmid">18566016</pub-id></citation>
      </ref>
      <ref id="B132-marinedrugs-10-02181">
        <label>132.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bidere</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lorenzo</surname>
              <given-names>H.K.</given-names>
            </name>
            <name>
              <surname>Carmona</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Laforge</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Harper</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Dumont</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Senik</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis</article-title>
          <source>J. Biol. Chem.</source>
          <year>2003</year>
          <volume>278</volume>
          <fpage>31401</fpage>
          <lpage>31411</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M301911200</pub-id><pub-id pub-id-type="pmid">12782632</pub-id></citation>
      </ref>
      <ref id="B133-marinedrugs-10-02181">
        <label>133.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaidi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Kalbacher</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Cathepsin E: A mini review</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <year>2008</year>
          <volume>367</volume>
          <fpage>517</fpage>
          <lpage>522</lpage>
        <pub-id pub-id-type="doi">10.1016/j.bbrc.2007.12.163</pub-id><pub-id pub-id-type="pmid">18178150</pub-id></citation>
      </ref>
      <ref id="B134-marinedrugs-10-02181">
        <label>134.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ali</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Rosati</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Pettit</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Kalemkerian</surname>
              <given-names>G.P.</given-names>
            </name>
          </person-group>
          <article-title>Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines</article-title>
          <source>Anticancer Res.</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>1021</fpage>
          <lpage>1026</lpage>
        <pub-id pub-id-type="pmid">9615758</pub-id></citation>
      </ref>
      <ref id="B135-marinedrugs-10-02181">
        <label>135.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pedersen</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>E.K.</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>The cytoskeleton and cell volume regulation</article-title>
          <source>Comp. Biochem. Physiol. A Mol. Integr. Physiol.</source>
          <year>2001</year>
          <volume>130</volume>
          <fpage>385</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="doi">10.1016/S1095-6433(01)00429-9</pub-id>
        </citation>
      </ref>
      <ref id="B136-marinedrugs-10-02181">
        <label>136.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maeno</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ishizaki</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kanaseki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hazama</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2000</year>
          <volume>97</volume>
          <fpage>9487</fpage>
          <lpage>9492</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.140216197</pub-id><pub-id pub-id-type="pmid">10900263</pub-id></citation>
      </ref>
      <ref id="B137-marinedrugs-10-02181">
        <label>137.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Segura</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Canizares</surname>
              <given-names>F.J.</given-names>
            </name>
            <name>
              <surname>Cubero</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Warley</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Changes in elemental content during apoptotic cell death studied by electron probe X-ray microanalysis</article-title>
          <source>Exp. Cell Res.</source>
          <year>1999</year>
          <volume>253</volume>
          <fpage>454</fpage>
          <lpage>462</lpage>
        <pub-id pub-id-type="doi">10.1006/excr.1999.4657</pub-id><pub-id pub-id-type="pmid">10585268</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
